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Accumulation of tau into insoluble aggregates known as neurofibrillary tangles (NFTs) is a pathological
hallmark of several neurodegenerative diseases, known as tauopathies. Aggregated proteins are normally
degraded by the cell’s protein degradation mechanisms, autophagy or the ubiquitin-proteasome system
(UPS). In tauopathies, however, the efficiency of these degradation pathways becomes challenged by the
abnormal accumulation of the tau protein, which consequently, does not get fully degraded. The current
hypothesis is that small, soluble oligomeric tau species preceding NFT formation cause toxicity. However,
thus far, visualizing the spatial distribution of tau monomers and oligomers inside cells under
physiological or pathological conditions has not been possible. Moreover, it is unclear whether certain tau
aggregate species are more resistant to degradation. Here, using single-molecule localization
microscopy, we show that tau forms small oligomers on microtubules ex vivo. These oligomers are
distinct from those found in cells exhibiting tau aggregation and could be precursors of aggregated tau in
pathology. Furthermore, using an unsupervised shape classification algorithm that we developed, we
show that different tau phosphorylation states are associated with distinct tau aggregate species. Using
machine learning, we also show that autophagy and UPS target distinct classes of tau aggregates for
degradation. More specifically, we propose a model where tau fibrils are targeted by UPS for degradation
and NFTs are mostly degraded by autophagy, generating more tau monomers and oligomers as well as
small fibrils. Our work elucidates tau’s nanoscale composition under nonaggregated and aggregated
conditions ex vivo and further informs our understanding of how tau aggregates become degraded by the
cell’s degradation pathways.
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ABSTRACT
TAKEN BY STORM: THE RISE AND FALL OF TAU FROM MICROTUBULE-ASSOCIATED TO
AGGREGATED TO DEGRADED
Melina Theoni Gyparaki
Melike Lakadamyali

Tau is a microtubule-associated protein, which promotes neuronal microtubule assembly
and stability. Accumulation of tau into insoluble aggregates known as neurofibrillary
tangles (NFTs) is a pathological hallmark of several neurodegenerative diseases, known
as tauopathies. Aggregated proteins are normally degraded by the cell’s protein
degradation mechanisms, autophagy or the ubiquitin-proteasome system (UPS). In
tauopathies, however, the efficiency of these degradation pathways becomes challenged
by the abnormal accumulation of the tau protein, which consequently, does not get fully
degraded. The current hypothesis is that small, soluble oligomeric tau species preceding
NFT formation cause toxicity. However, thus far, visualizing the spatial distribution of tau
monomers and oligomers inside cells under physiological or pathological conditions has
not been possible. Moreover, it is unclear whether certain tau aggregate species are more
resistant to degradation. Here, using single-molecule localization microscopy, we show
that tau forms small oligomers on microtubules ex vivo. These oligomers are distinct from
those found in cells exhibiting tau aggregation and could be precursors of aggregated tau
in pathology. Furthermore, using an unsupervised shape classification algorithm that we
developed, we show that different tau phosphorylation states are associated with distinct
tau aggregate species. Using machine learning, we also show that autophagy and UPS
target distinct classes of tau aggregates for degradation. More specifically, we propose a
model where tau fibrils are targeted by UPS for degradation and NFTs are mostly
vii

degraded by autophagy, generating more tau monomers and oligomers as well as small
fibrils. Our work elucidates tau’s nanoscale composition under nonaggregated and
aggregated conditions ex vivo and further informs our understanding of how tau
aggregates become degraded by the cell’s degradation pathways.
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CHAPTER 1. INTRODUCTION
Tau protein
Tau is a microtubule-associated protein (MAP), which is encoded by the MAPT gene on
chromosome 17 in humans (Neve et al. 1986). Transcription of the MAPT gene generates
6 tau protein isoforms by alternative splicing of exons 2, 3 and 10 in the central nervous
system (CNS) (Goedert et al. 1989). Tau protein consists of an N-terminal region followed
by microtubule-binding domains, a proline-rich region and a C-terminal region. The 6 tau
isoforms differ in the amount of microtubule-binding domains and amino-terminal inserts
they contain (Fig. 1.1A). Including exon 10 results in 4 microtubule-binding domains (4R),
while omitting exon 10 results in 3 microtubule-binding domains (3R). Similarly, tau can
have 2, 1 or 0 amino-terminal inserts (2N, 1N or 0N) through regulation of exons 2 and 3.
In the peripheral nervous system (PNS), production of larger tau proteins can occur by
transcription of exons 4A, 6 and 8 (Goedert, Spillantini, and Crowther 1992) (Fischer and
Baas 2020). All 6 tau isoforms are present in the adult human brain while only 0N3R is
present in the fetal human brain (T. Guo, Noble, and Hanger 2017). Mice and rats mostly
express 4R tau (T. Guo, Noble, and Hanger 2017). Tau is evolutionary conserved and
evidence of a MAPT-like gene has been found in many organisms, including sharks,
hagfish and lampreys (Sündermann, Fernandez, and Morgan 2016). Tau’s evolutionary
conservation suggests that it must perform essential biological functions.
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Figure 1.1: Tau in physiology and pathology.
A. Tau’s different isoforms and their structural domains. Created with BioRender.com. B. A model
of the tau aggregation pathway. Created with BioRender.com.

Tau structure
Tau is a highly soluble, heat-stable, intrinsically disordered protein (IDPs) with a transient
secondary structure (Battisti et al. 2012). As with other IDPs, tau’s conformation can
change depending on whether or not it is associated with other proteins. Tau’s
microtubule-binding domains associate with the building blocks of microtubules, α- and βtubulin proteins. More specifically, tau binds dynamically at the interface of tubulin
heterodimers via a group of conserved tau residues (Kadavath et al. 2015). Recently,
Cryo-Electron Microscopy (Cryo-EM) combined with molecular modeling showed that tau
binds along the microtubule protofilament, therefore stapling together tubulin subunits and
stabilizing the tubulin polymer (Kellogg et al. 2018). The peptide 275KVQIINKK280 between
regions 1 and 2 of the microtubule-binding domains (R1-R2), which is unique to the 4R
2

isoforms, strongly induces microtubule polymerization leading to greater microtubule
affinity for 4R isoforms compared to 3R (Goode and Feinstein 1994). Tau’s N-terminal
projection domain projects away from the microtubule surface and can interact with the
neuronal plasma membrane, membranous compartments such as mitochondria as well
as other cytoskeletal elements (Jung et al. 1993) (Brandt, Léger, and Lee 1995). The
projection domain is particularly important for maintaining proper spacing between axonal
microtubules (Chen et al. 1992). Tau’s proline-rich region has been shown to bind to the
Src-homology 3 (SH3) domains of Fyn kinase protein, which has a role in protein trafficking
(Reynolds et al. 2008) (Baba et al. 2009).
Tau’s structure is also affected by post-translational modifications of its residues.
Specifically, tau phosphorylation can facilitate the formation of α- and β-helices giving tau
a secondary structure (Grundke-Iqbal et al. 1986) (Bancher et al. 1989). Moreover, tau
hyperphosphorylation is thought to be involved in the formation of large insoluble tau
aggregates known as paired-helical filaments (PHFs) and neurofibrillary tangles (NFTs)
as it can affect tau’s affinity for microtubules and is therefore linked to tau’s dissociation
from the microtubules (Grundke-Iqbal et al. 1986). However, it is not fully understood
whether phosphorylation happens before or after PHF formation. It has been suggested
that phosphorylation could stabilize the α-helix structure on tau (Sibille et al. 2012).
Tau’s physiological role as a microtubule-associated protein
Tau has been traditionally thought to stabilize axonal microtubules (Drechsel et al. 1992)
and to be involved in microtubule assembly and dynamics influencing neuron morphology
(Drubin and Kirschner 1986) (Panda, Miller, and Wilson 1999). Moreover, tau is known to
have roles in axon development and navigation (Dawson et al. 2001) (Sayas et al. 2015).
3

Early work showed that tau reduces the tubulin concentration required for microtubule
polymerization (Weingarten et al. 1975). More recently, tau’s role as a regulator of
microtubule dynamics was proposed. More precisely, rather than stabilizing microtubules,
it was suggested that tau allows microtubules to have long labile domains, which would
explain why tau’s concentration increases toward the distal, more labile end of
microtubules (Qiang et al. 2018).
It has also been hypothesized that tau could be competing with motor proteins for
microtubule binding and its overexpression could potentially cause obstacles and “traffic
jams” for organelles and other proteins (Stamer et al. 2002) (Ebneth et al. 1998)(Dixit et
al. 2008). In particular, it was recently suggested that in physiological conditions,
concentrated regions of tau on neuronal axons, described as “cohesive islands” could be
leading to kinesin-1 dissociation from the microtubules, while dynein is thought to slowly
move through them (Siahaan et al. 2019) (R. Tan et al. 2019). However, this view is
challenged by studies reporting that axonal transport dynamics are not altered by tau’s
knockdown or overexpression. Further, the “kiss-and-hop” mechanism of tau suggests
that tau binding on microtubules is transient and hence should not disrupt other protein
binding sites (Yuan et al. 2008) (Janning et al. 2014).
Furthermore, there is evidence that tau protects microtubules from cleavage by the
microtubule-severing protein katanin and knockdown of tau results in cleavage and loss
of microtubules as well as reduced axonal length (Siahaan et al. 2019) (R. Tan et al. 2019)
(Qiang et al. 2006) (Yu et al. 2008). Tau depletion or mislocalization away from the axon
may therefore render microtubules vulnerable to cleavage. Additionally, tau may be crucial
for maintaining the non-branched structure of the axon as tau depletion results in an
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increase in neuronal branching, normally seen in dendrites which have low tau expression
(Yu et al. 2008).
Tau in pathology
Tau has disease relevance and its abnormal aggregation is a characteristic of several
neurodegenerative diseases including Alzheimer’s disease, which are collectively known
as tauopathies. Other tauopathy examples include progressive supranuclear palsy, Pick’s
disease, corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE) as
well as some frontotemporal dementias (Orr, Sullivan, and Frost 2017). In the case of
familial tauopathies, such as some frontotemporal dementias, there can be mutations in
the MAPT gene, which usually occur either in the microtubule-binding region of tau or can
affect the number of microtubule-binding domains of the tau protein. Such familial
tauopathies are associated with hyperphosphorylated, aggregated tau indicating that the
mutations alone are sufficient to induce pathogenic tau formation (Poorkaj et al. 1998)
(Hutton et al. 1998)(Spillantini et al. 1998)(Ghetti et al. 2015). Moreover, pathological tau
aggregates from different tauopathies often involve different tau isoforms. For instance,
while AD has a mix of 3R and 4R tau aggregates, Pick’s disease is characterized by strictly
3R tau aggregates and progressive supranuclear palsy by 4R tau aggregates (G. Lee and
Leugers 2012). It is also possible that tau isoforms are differentially expressed in certain
brain regions depending on the tauopathy, which is the case for tau isoforms in AD and
CTE, which are differentially expressed across the hippocampus (Cherry et al. 2021).
Also, the nature of tau protofilaments can vary depending on the tauopathy with some
protofilaments being disease-specific, which has made the idea of structure-specific tau
strains prevalent in recent years (Fitzpatrick et al. 2017) (Sanders et al. 2014) (Falcon et
al. 2018) (Falcon et al. 2019) (W. Zhang et al. 2019a). More specifically, the structure of
5

paired helical filaments (PHFs) and straight filaments (SFs) from AD brains was found to
have a similar C-shaped conformation involving repeats 3, 4 and R’ in CTE, but in the
case of CTE there were two packing arrangements between the protofilaments known as
Type I and II (Fitzpatrick et al. 2017) (Falcon et al. 2019). Cryo-EM work revealed some
further differences in the conformations of fibrils in CBD, which were also grouped in two
categories, Type I and II (W. Zhang et al. 2020). Recent work showed that tau PTMs
influence tau filament structure and contribute to the structural diversity of different tau
strains (Arakhamia et al. 2020). Interestingly, the transmission of distinct tau strains does
not depend on strain isoform compositions but instead on their unique pathological
conformations (He et al. 2020).
The tau aggregation pathway is not fully understood but a prominent model suggests that
tau falls off the microtubule following its hyperphosphorylation at multiple residues, initially
forming small, soluble aggregates also known as oligomers, and later forming larger
insoluble aggregates such as PHFs and NFTs (V. M. Y. Lee, Goedert, and Trojanowski
2001) (Fig. 1.1B). This model has not been fully validated and there is evidence that
contradicts it. NFTs were initially thought to be the most toxic tau species as they could
be detected in post-mortem brains of AD patients (Guillozet et al. 2003) (Santacruz et al.
2005). However, work from animal models showed that neurodegeneration leading to
synaptic dysfunction and behavioral abnormalities can occur in the absence of NFTs
(Wittmann et al. 2001) (Cowan et al. 2010). Additionally, NFTs can persist for 20-30 years
in neurons, which makes them less likely to be causing immediate toxicity (Morsch, Simon,
and Coleman 1999). Currently, the most likely hypothesis is that earlier stages of the tau
aggregation pathway are responsible for tau toxicity, particularly tau oligomers. Injecting
tau oligomers into the brains of wild-type mice is sufficient to cause synaptic and cognitive
6

abnormalities (Lasagna-Reeves et al. 2011) (Castillo-Carranza et al. 2014). Moreover, tau
oligomers have been associated with synaptic loss in transgenic mice expressing wildtype human tau (Spires et al. 2006) (Berger et al. 2007) (Clavaguera et al. 2013).
The nature of tau oligomers
Tau oligomers are most commonly associated with tau pathology. Soluble tau oligomers
have been isolated from homogenized AD brains (Patterson et al. 2011). It has also been
reported that tau oligomers can become insoluble by lengthening and adopting a β-sheet
conformation, which gives them a granular appearance under atomic force microscopy
(AFM) (Takashima 2013). However, it is not clear whether tau oligomers are solely a
pathological feature. In vitro studies have shown that tau with the disease relevant P301L
mutation isolated from yeast and wild-type tau isolated from rats can form tau clusters and
oligomers on taxol-stabilized microtubules, respectively (Vandebroek et al. 2006)
(Makrides et al. 2003). Moreover, the formation of an electrostatic zipper between the Nterminal halves of two tau molecules aligned in an anti-parallel fashion, is thought to
facilitate tau dimerization (Rosenberg et al. 2008). Protein dimerization is an evolutionary
favored mechanism to promote protein complex formation in physiological settings in
addition to pathology (Marianayagam, Sunde, and Matthews 2004). Therefore, it is
possible that tau can also dimerize and oligomerize to promote its physiological functions
and is not only associated with its pathological state.
Despite the extensive in vitro characterization of tau oligomers, visualizing them in intact
cells has been a challenge due to their small size and the resolution constraints of
conventional light microscopy. Elucidating the nanoscale composition of tau on
microtubules, in tau oligomers as well as in other tau aggregates is essential to improve
7

our understanding of the mechanisms that lead to pathological tau generation and
propagation as well as in the search for therapeutic targets for tauopathies.
Degradation of tau aggregates
The over accumulation of tau aggregates in tauopathies is partly due to their inefficient
clearance by UPS and autophagy, which normally degrade aggregated proteins in cells.
UPS traditionally degrades short-lived poly-ubiquitinated proteins that are smaller in size
to fit through the proteolytic core of the proteasome complex, while autophagy degrades
larger proteins, aggregates and damaged organelles via the formation of the
autophagosome which fuses into the lysosome where degradation occurs (Lilienbaum
2013). Since tau is naturally unfolded, it is a good candidate for UPS degradation in its
monomeric state, while larger aggregates are thought to be degraded by autophagy due
to their size (Bence, Sampat, and Kopito 2001) (Hamano et al. 2021). It is known that
proteasome activity decreases in the aging brain and is lower in brain areas, which are
abundant in NFTs (Keller, Gee, and Ding 2002) (Keller, Hanni, and Markesbery 2000).
Moreover, in vitro studies have shown that aggregated tau can interact with the
proteasome and inhibit its function (Keck et al. 2003). Recently, in a mouse model of
tauopathy, accumulation of insoluble tau correlated with a decrease in proteasome activity
and an increase in ubiquitinated proteins, while activating cAMP-protein kinase (PKA)
signaling led to improvement of proteasome function and cognitive performance as well
as lower levels of aggregated tau (Myeku et al. 2016). Therefore, the proteasome must be
involved in the clearance of some tau aggregate species which can fit through its
proteolytic core and is not limited to degrading monomeric tau species. Indeed, there is in
vitro evidence supporting UPS-mediated tau aggregate degradation (David et al. 2002).
Moreover, in studies using cell systems, the addition of proteasome inhibitors leads to an
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accumulation of insoluble tau shown biochemically (Babu, Geetha, and Wooten 2005).
However, the nature of the insoluble tau species accumulating is yet to be elucidated.
Similarly, there is evidence of autophagy defects such as accumulation of autophagic
vacuoles in dystrophic neurites being associated with the presence of filamentous tau
seen in AD brains (Nixon et al. 2005) (Sanchez-Varo et al. 2012). In fact, it is thought that
the autophagic pathology seen in AD brains is more likely due to autophagy defects rather
than activated autophagy (Boland et al. 2008). Inhibiting autophagy leads to accumulation
of tau aggregates sometimes both soluble and insoluble species (Hamano et al. 2008).
Furthermore, pharmacological activation of autophagy has also been shown to lead to
increased clearance of tau aggregates, but as with UPS, the selectivity of the autophagy
pathway when degrading tau has not been yet delineated (Congdon et al. 2012) (Krüger
et al. 2012). Understanding the pathways that degrade tau and the selectivity of these
pathways for different tau species is of great interest in the field.
Tau therapeutic targets
To this day, there are no effective treatments for tauopathies due to the lack of effective
therapeutic targets and our limited understanding of the mechanisms of pathological tau
generation, which deems tauopathies to be diseases of great complexity. Since tau
phosphorylation is the most well-studied post-translational modification of tau and tau
hyperphosphorylation is considered a pathological feature of tauopathies, there has been
great interest in identifying inhibitors of the kinases catalyzing these increased tau
phosphorylation events. GSK-3β and CDK5 kinases are among the most well studied
kinases which phosphorylate tau (Tell and Hilgeroth 2013) (Martin et al. 2013). It has been
shown that their inhibition reduces tau phosphorylation and tau deposits in mouse models
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of tauopathy but it did not offer cognitive improvements to AD patients in a Phase 2 clinical
trial (Noble et al. 2005) (Le Corre et al. 2006). Moreover, there is potential in inhibiting
other tau post-translational modifications such as O-linked glycosylation and lysine
acetylation. An inhibitor of O-linked glycosylation has been shown to reduce tau
phosphorylation and the presence of insoluble tau deposits in a transgenic mouse model
of tauopathy (Yuzwa et al. 2008). However, those findings have been inconsistent in
different studies meaning that inhibition of O-linked glycosylation on its own is not the most
effective approach (Borghgraef et al. 2013). Inhibitors of tau acetylation have also shown
promise in transgenic mouse models of tauopathy, where there was an improvement in
neuron loss (Min et al. 2015).
Another therapeutic approach has been to reduce microtubule dynamics in an attempt to
counteract the increased dynamicity of microtubules, and other microtubule deficits seen
in mouse models of tauopathy following tau’s dissociation from the microtubules in
pathology (Hempen and Brion 1996)(Cash et al. 2003). More precisely, there have been
multiple therapeutic strategies using microtubule stabilizing drugs such as paclitaxel.
Results in mouse models have been promising, however, paclitaxel is not blood brain
barrier permeable (B. Zhang et al. 2005) (Brunden et al. 2011). Other microtubule
stabilizing drugs that are blood brain barrier permeable have been identified without much
success in the clinic (B. Zhang et al. 2012) (Brunden et al. 2010). One of the main
challenges of this approach is the toxic effects of the anti-mitotic properties these drugs
have in non-neuronal cells.
Inhibiting tau fibrillization had initially shown some promise but has not had much success
in clinical trials mostly due to the fact that most fibrillization inhibitors act via unknown
mechanisms and could be targeting other pathways leading to adverse effects (Wischik
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et al. 2015) (Crowe et al. 2007) (Arkin and Wells 2004) (Akoury et al. 2013). Inhibiting
proteolytic processing of tau and improving cellular proteostasis are very promising
approaches. However, there are many gaps in our knowledge that currently prevent
identifying suitable therapeutic targets in these areas. More specifically, it is thought that
cellular proteases such as caspase, calpain, cathepsin and others can cleave tau in a way
which generates pathological tau species (Rissman et al. 2004) (Ferreira and Bigio 2011)
(Bi et al. 2000). In addition, the large selection of enzymes that can process tau hinder the
determination of how they are all connected and whether some are more important than
others. Similarly, improving cellular proteostasis is appealing but comes with challenges.
For instance, it is not clear whether tau oligomers would only be degraded by autophagy
or whether they could also be degraded by UPS. The big gap in our knowledge in this field
is that it is not clear which tau aggregate species could be degraded by each pathway and
how these tau aggregates impact the protein degradation systems altogether. Elucidating
those protein degradation mechanisms of tau aggregates has the potential to yield new
therapeutic target candidates.
Currently, one of the most pursued therapeutic avenues for neurodegenerative diseases
is immunotherapy (Pedersen and Sigurdsson 2015). Initially, a major concern regarding
immunotherapy was whether sufficient intraneuronal antibody concentrations could be
achieved in the brain since antibody concentration in the brain is only approximately 0.1%
of that in the blood. However, recent work has shown that tau inclusions most likely follow
a prion-like method of transmission suggesting that pathological tau released
extracellularly could be accessible to antibodies in the interstitial fluid of the brain, thus
making immunotherapy a promising approach (Pedersen and Sigurdsson 2015)
(Schroeder et al. 2016).
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Visualizing tau in physiology and pathology
Electron microscopy (EM) approaches have been very informative regarding the structure
of the tau protein both in physiology and pathology. Most of our knowledge on the
composition of tau filaments and aggregates is thanks to EM and more recently, cryo-EM
approaches (Necula and Kuret 2004) (Huseby and Kuret 2016) (Fitzpatrick et al. 2017)
(Scheres et al. 2020). Recently, Cryo-EM also provided further insight into how wild type
tau binds along the microtubule protofilament in physiology (Kellogg et al. 2018). Similarly,
other in vitro approaches such as AFM have provided further structural insight into tau,
specifically tau oligomers and fibrils (Wegmann, Muller, and Mandelkow 2012)(Makky et
al. 2020)(Barrantes et al. 2009).
However, there are still many unknowns regarding tau’s distribution in intact neurons. One
of the main challenges of visualizing tau in intact cells has been the fact that tau is
associated with the very dense axonal microtubule network of neurons and conventional
light microscopy approaches cannot fully resolve its nanoscale composition due to the
diffraction limit of spatial resolution in light microscopy. In conventional microscopy
images, microtubule-associated tau is seen to fully occupy the tubulin polymer
demonstrating a uniform distribution (Agostini et al. 2013). However, these images can be
misleading as the resolving power is not sufficient to determine the distribution of the tau
protein as individual tau molecules are smaller than 200 nm, which is the approximate
resolution limit of these approaches.
Single-molecule localization microscopy (SMLM) approaches can exceed the resolution
limit of conventional light microscopy approaches often reaching down to 20nm spatial
resolution (Lelek et al. 2021) (Betzig et al. 2006) (Hess, Girirajan, and Mason 2006) (Rust,
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Bates, and Zhuang 2006) (Heilemann et al. 2008). One such approach is known as
STochastic Optical Reconstruction Microscopy or STORM (Rust, Bates, and Zhuang
2006). STORM typically uses fixed samples which are stained with photoswitchable
fluorophores and imaged in a special buffer. The buffer contains thiols such as
Cysteamine (also known as MEA), which are necessary for photoswitching. Additionally,
the buffer contains an oxygen scavenger system, specifically glucose oxidase and
catalase, which is important for reducing photobleaching (Lelek et al. 2021). This STORM
buffer in combination with the photoswitchable molecules in the sample allow some
molecules to stochastically activate, while the rest are in a dark state. Once a molecule is
stochastically activated, its centroid position can be localized with nanoscale precision.
Once all molecules in the sample have been activated, the resulted reconstructed image
or STORM image containing localizations from all the fluorescent molecules in the sample
is produced (Fig. 1.2). The localizations in the image can then be rendered with a
Gaussian blur for visualization purposes and analyzed further with several quantitative
approaches (Lelek et al. 2021).

Figure 1.2: STORM imaging
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The two fluorophores (magenta and green circles) on the left cannot be resolved due to the
diffraction limit and instead appear as the unresolved blob on the right (blue). In STORM, during
the blinking phase of the photoswitchable molecules, the fluorophore on the left (magenta) can be
stochastically activated while the molecule on the right (green) is in an off state. Once all molecules
have been activated a reconstructed STORM image (bottom right) is obtained.

In this work, we have used a combination of STORM and machine learning to study i) the
nanoscale composition of tau on microtubules and in tau aggregates, and ii) which tau
aggregate species are degraded by UPS versus autophagy. More specifically, in Chapter
2, I will show how we tested the hypothesis that tau has a non-uniform distribution on the
microtubules and that this distribution is different when tau is aggregated. In Chapter 3, I
will show how we tested whether different tau aggregate species have prominent
phosphorylation markers. In Chapter 4, I will discuss how UPS and autophagy differentially
degrade different tau aggregate species. Finally, in Chapter 5, I will summarize our
findings and provide future directions for our work.
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CHAPTER 2. TAU FORMS OLIGOMERIC COMPLEXES ON MICROTUBULES
THAT ARE DISTINCT FROM TAU AGGREGATES
Adapted from article published as: Gyparaki, M. T., Arab, A., Sorokina, E. M., SantiagoRuiz, A. N., Bohrer, C. H., Xiao, J. and Lakadamyali, M. (2021). Tau forms oligomeric
complexes on microtubules that are distinct from tau aggregates. PNAS, 118,
e2021461118 (19). PNAS authors do not need permission to include their articles as part
of their dissertation.
Introduction

Tau is a microtubule-associated protein mainly expressed in neurons. Tau is an
intrinsically disordered protein, which facilitates the assembly and stability of neuronal
microtubules. Immunofluorescence labeling showed that tau is highly abundant in
neuronal axons and shows a graded distribution with higher concentration toward the axon
terminal (Weissmann et al. 2009). Tau binding is thought to stabilize neuronal
microtubules, although this idea has recently been called into question, and recent work
suggests that tau may bind the more labile part of microtubules, enabling them to have
long labile domains (Qiang et al. 2018). The first near-atomic model of tau bound to
microtubules obtained using cryogenic electron microscopy (cryo-EM) and computational
modeling revealed that tau binds along the microtubule protofilament, stabilizing the
interface between tubulin dimers (Kellogg et al. 2018). Tau has also been shown to
undergo liquid–liquid phase separation in vitro, and tau condensates have been proposed
to facilitate microtubule polymerization due to their ability to sequester soluble tubulin
(Wegmann et al. 2018). In vitro reconstitution experiments further showed that tau forms
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liquid condensates that are several microns in size on taxol-stabilized microtubules, and
these tau “islands” regulate microtubule severing and microtubule–motor protein
interactions (R. Tan et al. 2019) (Siahaan et al. 2019). However, despite progress, the
distribution of tau on microtubules in intact cells and the physiological relevance of tau
condensates are unclear.

Under pathological conditions, tau becomes hyperphosphorylated and detaches from
microtubules, leading to the misfolding and formation of tau aggregates in the cytosol
(Grundke-Iqbal et al. 1986). Accumulation of tau into insoluble aggregates known as
neurofibrillary tangles (NFTs) is a hallmark of several neurodegenerative diseases such
as Alzheimer’s disease (AD) and frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), which are collectively known as tauopathies. Liquid phase
separation has also been suggested to play a role in pathological tau aggregation, as
aggregation-prone tau mutants have an increased propensity to undergo liquid phase
separation (Wegmann et al. 2018). Recently, cryo-EM studies have also revealed the
high-resolution structures of insoluble tau aggregates, including paired helical filaments
(PHF) and straight filaments (SFs) from AD brain (Fitzpatrick et al. 2017). While these
insoluble aggregates such as PHFs, SFs, and NFTs have traditionally been considered
the pathological tau species, recent evidence from animal models has shown that
neurodegeneration in terms of synaptic dysfunction and behavioral abnormalities can exist
without the presence of NFTs (Wittmann et al. 2001) (Cowan et al. 2010).

The current hypothesis is that earlier stages of tau aggregation initiate pathology. In
particular, small, soluble tau oligomeric species preceding the formation of NFTs could be
the cause of loss of tau function and toxicity. Soluble tau oligomers have been isolated
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from homogenized AD brains and detected on sodium dodecyl sulfate–polyacrylamide gel
electrophoresis gels (Patterson et al. 2011). These tau oligomers have also been
implicated in synaptic loss in transgenic mice expressing wild-type human tau (Spires et
al. 2006) (Berger et al. 2007) (Clavaguera et al. 2013). Moreover, injection of tau oligomers
rather than monomers or fibrils into the brain of wild-type mice was sufficient to produce
cognitive and synaptic abnormalities (Lasagna-Reeves et al. 2011) (Castillo-Carranza et
al. 2014). Tau oligomers can lengthen and adopt a β-sheet conformation, which renders
them detergent insoluble. Such oligomers have granular appearance under atomic force
microscopy (AFM) (Takashima 2013).

Despite their in vitro characterization, to date, there have not been studies visualizing and
characterizing the formation of these small oligomers in intact cells due to the lack of
quantitative, high-resolution tools. The lack of sensitive tools that enable visualizing the
spatial distribution and quantifying the stoichiometry of tau complexes within native and
diseased neurons prevents progress in studying the mechanisms that lead to pathological
tau oligomerization and the impact of early stages of tau aggregation on cellular
processes.

Here, we have used quantitative super-resolution microscopy to visualize and determine
the nanoscale organization of tau in various engineered cells modeling the nonaggregated
state of tau (QBI-293 Clone 4.0 cells expressing 4R-P301L-GFP tau, BSC-1 cells
expressing 3R-WT-GFP tau, and BSC-1 cells expressing 4R-WT-GFP tau) (J. L. Guo et
al. 2016) as well as in rat hippocampal neurons. In addition, using an engineered cell
model expressing tau harboring the FTDP-17 mutation P301L and transduced with
exogenous tau fibrils to mimic tau aggregation in disease (QBI-293 Clone 4.1 cells
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expressing 4R-P301L-GFP tau) (J. L. Guo et al. 2016), we characterized the nature of tau
aggregates including oligomeric tau species. Surprisingly, our results show that, in
engineered cell lines modeling a nonaggregated state of tau, tau forms a patchy
distribution consisting of nanoclusters along the microtubule. Tau nanoclusters mainly
correspond to monomeric, dimeric, and trimeric tau complexes. The nanoscale distribution
of microtubule-associated tau in these engineered cells resembles the nanoscale
distribution of microtubule-associated endogenous tau in hippocampal neurons isolated
from rats. In engineered cell lines modeling an aggregated state of tau (QBI-293 Clone
4.1), tau forms a diverse range of aggregate species, including small oligomeric tau
assemblies, small fibrillary structures, branched fibrils, and large plaque-like structures
resembling NFTs. The oligomeric species found in the aggregated tau cell model are
partially microtubule associated and are distinct from the monomers, dimers, and trimers
found in the nonaggregated cell models and in neurons, since they are larger, containing
more tau molecules.

Overall, we present a detailed, quantitative characterization of tau oligomers on
microtubules in intact cells and of tau aggregates with nanoscale resolution in a cell model
of FTDP-17.

Results
Microtubule-Associated Tau Is Partially Oligomeric under Nonaggregated
Conditions.

To determine how tau is distributed when it is associated to microtubules under
nonaggregated conditions, we performed single-molecule localization microscopy
(SMLM) in various engineered cell models: a stable BSC-1 cell line that constitutively
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expresses the 3R isoform of wild-type (WT) tau fused to green fluorescent protein (GFP;
BSC-1 3R-WT-GFP tau), BSC-1 cells transiently expressing the 4R isoform of WT tau
fused to GFP (BSC-1 4R-WT-GFP tau), and an inducible QBI-293 cell line that stably
expresses GFP-tagged tau harboring a FTDP-17 mutation (P301L) under the control of
doxycycline (Dox) (QBI-293 Clone 4.0 4R-P301L-GFP tau, referred to as Clone 4.0 in the
rest of the manuscript). The pattern of GFP expression in all the engineered cell lines we
imaged resembles the microtubule network (SI Appendix A, Fig. A1A), indicating that tau
is predominantly microtubule associated in all cases as expected. Additionally, we
transiently expressed the 4R-WT tau (without GFP fusion) in BSC-1 cells and detected
tau localization using immunofluorescence labeling with a Tau-5 antibody. The 4R-WT tau
formed a microtubule-associated pattern in cells similar to the GFP-fused 4R-WT tau (SI
Appendix A, Fig. A1A). Hence, GFP-fused tau is able to bind microtubules in cells.

Since these engineered cell lines do not endogenously express tau or express it at very
low levels (SI Appendix A, Fig. A1B), using the inducible Clone 4.0 cells as the model, we
asked whether when tau expression is induced by Dox, the binding of tau to the
microtubules impacts the microtubule network. To address this question, we imaged the
microtubule network in Clone 4.0 before and after Dox induction using SMLM. As
expected, tau expression led to increased microtubule density and microtubule bundling
in line with the known functions of tau in facilitating microtubule polymerization and
bundling (SI Appendix A, Fig. A1 C, Top and Middle and SI Appendix A, Fig. A1D, first two
plots) (Kanai, Chen, and Hirokawa 1992) (Fauquant et al. 2011). These results further
support that GFP-fused tau is able to induce microtubule polymerization and bundling.
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We next labeled 4R-P301L-GFP tau (Fig. 2.1A and additional representative images in SI
Appendix A, Fig. A2A), 3R-WT-GFP tau (Fig. 2.1B), and 4R-WT-GFP tau (SI Appendix A,
Fig. A2B) in the corresponding cell models with a GFP nanobody conjugated with a
photoswitchable fluorescent dye (AF647) to image tau’s nanoscale distribution with
SMLM. To ensure that fixation did not perturb tau localization, we tested two commonly
used fixation protocols using either aldehyde-based fixation (paraformaldehyde, PFA) or
alcohol-based fixation (methanol) (SI Appendix, Materials and Methods). PFA fixation led
to a mislocalization of tau and loss of “microtubule-like” staining visible in live cells (SI
Appendix A, Fig. A3A) in line with previous reports (Ebneth et al. 1998) (Illenberger et al.
1998). Methanol fixation, on the other hand, preserved the microtubule localization of tau
(SI Appendix A, Fig. A3A). Indeed, when we determined the fluorescence intensity of
microtubule-associated 4R-P301L-GFP tau in the same Clone 4.0 cells before and after
methanol fixation, the fluorescence intensity was only reduced by a small amount (mean
intensity: 871.2 AU before and 750.1 AU after fixation), suggesting that the majority of tau
remains microtubule bound after fixation (SI Appendix A, Fig. A3B). Hence, we used
methanol fixation for visualizing tau’s nanoscale organization.
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Figure 2.1: Microtubule-associated tau is partially oligomeric under nonaggregated conditions
A. Super-resolution image of tau in Clone 4.0 cells expressing 4R-P301L-GFP tau stained with
GFP nanobody conjugated to Alexa Fluor 647 after overnight Dox induction of tau expression.
(Inset) Pictured together with corresponding Voronoi segmentation. Segmented images are
pseudo color coded with different colors corresponding to different segmented nanoclusters.
B. Super-resolution image of tau in stable BSC-1 cells constitutively expressing 3R-WT-GFP
tau stained with GFP nanobody conjugated to Alexa Fluor 647. (Inset) Pictured together with
corresponding Voronoi segmentation. Segmented images are pseudo color coded with
different colors corresponding to different segmented nanoclusters. C. Super -resolution image
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of oligomeric tau detected by the tau oligomer-specific T22 antibody in Clone 4.0 cells
expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression. (Inset) Pseudo
color-coded Voronoi segmentation of nanoclusters. D. Violin plots showing the number of
localizations per nanocluster segmented with Voronoi segmentation in the different cell lines
used in this study (green: Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression; yellow: stable BSC-1 cells constitutively expressing 3R-WT-GFP
tau; and cyan: rat hippocampal neurons). Plots for A and B correspond to the quantification of
tau nanoclusters stained and imaged with a GFP nanobody. Plot for H corresponds to the
quantification of tau nanoclusters stained and imaged with a Tau -5 antibody. Plots
for C and I correspond to the quantification of tau nanoclusters stained and imaged with the
oligomeric T22 antibody. The dashed lines indicate the median, and the dotted lines indicate
the 25th and 75th percentile. (A) n = 15 cells, n = 3 experiments. (B) n = 15 cells, n = 2
experiments. (C) n = 19 cells, n = 3 experiments. (H) n = 3 cells. (I) n = 3 cells. E. Two-color
super-resolution images of α-tubulin (magenta), total tau (cyan), and overlay in Clone 4.0 cells
expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression. The results of
the colocalization analysis are shown in which tau nanoclusters colocalized with α-tubulin are
color coded in magenta, and isolated tau nanoclusters are shown in yellow. F. Two -color superresolution images of oligomeric tau detected by tau oligomer-specific T22 antibody (magenta),
total tau (cyan), and overlay in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight
Dox induction of tau expression. The results of the colocalization analysis are shown in which
tau nanoclusters colocalized with T22 are color coded in magenta, and isolated tau
nanoclusters are shown in yellow. G. Violin plots showing the percentage of tau nanoclusters
colocalized with α-tubulin and T22 antibodies in Clone 4.0 cells expressing 4R-P301L-GFP tau
after overnight Dox induction of tau expression (green) and Clone 4.1 cells maintained in Dox
and expressing 4R-P301L-GFP tau (pink). (Tubulin in Clone 4.0: n = 9 cells, n = 2 experiments;
Tubulin in Clone 4.1: n = 7 cells, n = 2 experiments; T22 in Clone 4.0: n = 9 cells, n = 3
experiments; T22 in Clone 4.1: n = 6 cells, n = 2 experiments). H. Super-resolution image of
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tau in rat hippocampal neurons, stained with Tau-5 antibody, which detects all tau isoforms.
(Inset) Pictured together with corresponding Voronoi segmentation. Segmented images are
pseudo color coded with different colors corresponding to diff erent segmented nanoclusters. I.
Super-resolution image of oligomeric tau detected by oligomer tau-specific T22 antibody in rat
hippocampal neurons. (Inset) Pseudo color-coded Voronoi segmentation of nanoclusters.

SMLM images revealed that both 3R (Fig. 2.1B) and 4R (SI Appendix A, Fig. A2B)
isoforms of WT tau as well as the 4R isoform harboring the P301L mutation (Fig.
2.1A and SI Appendix A, Fig. A2A) are not uniformly distributed on the microtubule, unlike
α-tubulin (compare Fig. 2.1 A and B and SI Appendix, Figs. A2A and B and A3C), but
instead form nanoclusters. We segmented these nanoclusters using Voronoi tessellation
(Levet et al. 2015) (Andronov et al. 2016) (Fig. 2.1A and B and SI Appendix A, Fig.
A3D and Materials and Methods) and quantified the number of localizations per
nanocluster (Fig. 2.1D) (corresponding to the number of times an AF647 fluorophore was
localized) as well as the nanocluster area (SI Appendix A, Fig. A3E), obtaining a broad
distribution in all cases. These parameters were similar for 3R-WT-GFP tau in stable BSC1 cells and 4R-P301L-GFP tau in Clone 4.0 cells, despite vast differences in expression
level between 3R-WT-GFP tau and 4R-P301L-GFP tau (fivefold difference in
expression, SI Appendix A, Fig. A3F). Furthermore, when we compared low and high GFP
tau-expressing BSC-1 cells transiently expressing the same tau construct (4R-WT-GFP
tau) and cultured in the same way (SI Appendix A, Fig. A3G, threefold difference in
expression), we found that tau formed nanoclusters in both high- and low-expressing cells.
Tau nanoclusters further contained only a slightly higher number of localizations in highexpressing cells compared to the low-expressing cells (median: 13 ± 36.58 for lowexpressing cells versus median: 15 ± 59.98 for high-expressing cells, SI Appendix A, Fig.
23

A3H). Previous work showed that 4R-P301L tau in Clone 4.0 cells remains soluble and
does not form insoluble tau inclusions for up to 2 d after Dox induction (J. L. Guo et al.
2016). To determine the impact of the duration of Dox induction on tau nanocluster
formation, we cultured and imaged Clone 4.0 cells for 1 or 2 d after Dox induction and
found that tau nanoclusters were similar for these time points (SI Appendix A, Fig. A3I).
Taken together, these results suggest that tau nanocluster formation does not strongly
depend on the type of tau isoform or the method of tau expression (transient,
stable/constitutive, or stable/inducible) and is only weakly dependent on the level of tau
expression. Since tau distribution was similar between two isoforms of WT tau and tau
harboring the P301L mutation, we used the inducible 4R-P301L-GFP tau Clone 4.0 cell
line for subsequent analysis.

To determine the monomeric versus oligomeric nature of tau within these nanoclusters,
we used a number of different approaches. In principle, the number of localizations per
nanocluster in SMLM images is proportional to the number of proteins. However, repeated
fluorophore blinking and the fact that the labeling ratio between the protein and the
fluorophore is often not one to one typically leads to overcounting artifacts (Durisic,
Cuervo, and Lakadamyali 2014).

First, to exclude the possibility that these are artificial nanoclusters resulting from repeated
blinking of the same fluorophore, we used Distance Distribution Correction (DDC) (Bohrer
et al. 2019) to eliminate multiple localizations from the same molecule. Although DDC
narrowed down the distribution of GFP tau nanocluster areas and the number of
localizations per cluster (SI Appendix A, Fig. A4 A–C), the distributions still remained
broad. Importantly, DDC correction did not eliminate the presence of nanoclusters (SI
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Appendix A, Fig. A4A), suggesting that these are not artificial nanoclusters due to
repeated fluorophore blinking.

Second, we used a commercial oligomeric tau antibody (T22) to specifically stain
oligomeric tau. SMLM images of tau labeled with the T22 antibody revealed a
discontinuous microtubule-like pattern, suggesting that the oligomeric T22 antibody binds
to microtubule-associated tau (Fig. 2.1C and additional representative images in SI
Appendix A, Fig. A2C).

Taken together, our analyses suggested that observed tau nanoclusters contain
oligomeric tau molecules associated with microtubules. To estimate the number of tau
molecules in these nanoclusters, we next used a method that we previously developed to
estimate the stoichiometry of proteins in super-resolution images using the number of
localizations distribution from the monomeric protein images as a calibration (Cella
Zanacchi et al. 2017). To determine the number of localizations distribution corresponding
to the monomeric protein, we performed a 100-fold dilution of the GFP nanobody to
sparsely label individual tau molecules instead of saturating all GFP epitopes. This
approach has previously been successfully used to calibrate antibody-labeled receptors
to determine their stoichiometry within synapses (Ehmann et al. 2014). The resulting
images under dilute labeling conditions showed “nanoclusters” that were much sparser
than those in densely labeled cells (SI Appendix A, Fig. A4D). Nanoclusters under dilute
labeling conditions also contained a significantly lower number of localizations compared
to those in densely labeled cells (SI Appendix A, Fig. A4E). We assumed that the
nanoclusters under sparse labeling conditions therefore mainly corresponded to
monomeric tau and appeared as nanoclusters because of repeated blinking of the same
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fluorophore. Indeed, DDC eliminated the appearance of nanoclusters (SI Appendix A, Fig.
A4F) and Voronoi segmentation of DDC-corrected images did not detect any nanoclusters
under dilute labeling conditions. Using the distribution of the number of localizations per
nanocluster prior to DDC correction under dilute labeling conditions as a calibration (SI
Appendix, Materials and Methods), we determined that tau nanoclusters in the densely
labeled 4R-P301L-GFP tau Clone 4.0 cells contain ∼60% monomers, ∼20% dimers, and
∼20% trimers (SI Appendix A, Fig. A4 G and H). Tau nanoclusters in the BSC-1 cells
stably expressing 3R-WT-GFP tau consisted of ∼60% monomers, ∼25% dimers, and
∼15% trimers, which is very similar to the percentages determined in the 4R-P301L-GFP
tau Clone 4.0 cell line (SI Appendix A, Fig. A4I).

To further support these results, we labeled tau together with α-tubulin or with T22 and
carried out two-color SMLM (Fig. 2.1 E and F). We used the images of microtubules or of
oligomeric tau labeled with T22 antibody as a mask and categorized the tau nanoclusters
into two populations: those that colocalize with the reference mask and those that are
isolated (SI Appendix A, Materials and Methods and Fig. 2.1 E and F). Approximately 61
± 19% of the GFP tau nanoclusters were microtubule associated (Fig. 2.1G). Similarly,
∼20 ± 7% of GFP tau nanoclusters colocalized with T22-stained tau oligomers (Fig. 2.1G).
A positive control experiment in which we labeled GFP tau with nanobodies in two colors
and carried out colocalization analysis showed ∼60 ± 13% colocalization under conditions
in which we expect full colocalization (SI Appendix A, Fig. A5A), consistent with previous
two-color super-resolution results(Spiess et al. 2018). Hence, our two-color imaging and
colocalization analysis underestimates the true extent of colocalization by ∼1.7-fold,
suggesting that tau is almost exclusively microtubule associated in Clone 4.0, and ∼34%
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of tau colocalizes with T22. The latter number is in line with our calibration and
stoichiometry estimation showing ∼40% tau dimers/trimers in Clone 4.0.

Finally, to confirm that the nanoclusters are not due to overexpression of the GFP fusion
protein in the engineered cell lines, we stained endogenous tau in hippocampal neurons,
which mainly express the 3R isoform of tau (Fuster-Matanzo et al. 2012), with a total tau
antibody, Tau-5 (Fig. 2.1H and additional representative images in SI Appendix A, Fig.
A2D) as well as T22 (Fig. 2.1I and additional representative images in SI Appendix A, Fig.
A2E). We obtained similar results in which tau formed nanoclusters containing a wide
distribution of a number of localizations that are recognized by the oligomeric tau T22
antibody (quantified in Fig. 2.1D and SI Appendix A, Fig. A3E). We repeated the dilute
labeling experiments by lowering the concentration of the primary Tau-5 antibody by 100fold while keeping the secondary antibody concentration at the same level in neurons.
Under dilute primary antibody labeling conditions, we obtained sparse nanoclusters
containing significantly fewer localizations and likely corresponding to monomeric tau
similar to the nanobody experiments (SI Appendix A, Fig. A4J). These results indicate that
tau oligomers are also present in physiological conditions in cultured neurons and are not
an artifact of GFP fusion.

Based on these results, we concluded that under physiological conditions in neurons and
under nonaggregated conditions in engineered cell lines, tau is primarily microtubule
associated, and a proportion of tau that is associated with microtubules forms dimeric and
trimeric complexes.
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Tau Oligomers in Cells Exhibiting Tau Aggregation Are Distinct from Tau
Oligomers in Nonaggregated Tau Cell Models.
To determine the nanoscale distribution and composition of tau aggregates, we used an
engineered cell line modeling tau aggregation: QBI-293 Clone 4.1 cells expressing 4RP301L-GFP tau under Dox control, which we will refer to as Clone 4.1 cells. Clone 4.1 is
a subclone of Clone 4.0 and was obtained after exogenously transducing the parent clone
(Clone 4.0) with in vitro reconstituted tau fibrils to induce tau aggregation and selected
because it stably maintains tau aggregates when cultured in the presence of Dox (J. L.
Guo et al. 2016). Western blot analysis showed that Clone 4.1 expresses tau at slightly
lower levels than Clone 4.0 (SI Appendix A, Fig. A1B), and hence, the tau aggregation
seen in Clone 4.1 is not a result of higher tau expression levels but instead is seeded by
the exogenously introduced tau fibrils.

Previous work using this subclone showed that it recapitulates the tau aggregation seen
in disease states, such as formation of large tau inclusions resembling NFTs (J. L. Guo et
al. 2016). Furthermore, it was shown that when tau expression is stopped by culturing the
Clone 4.1 cells off Dox, tau aggregates are cleared via lysosomal degradation (J. L. Guo
et al. 2016). These previous results suggest that Clone 4.1 is a good model system for
pathological tau aggregation and for gaining new insights into mechanisms of tau
aggregation and clearance ex vivo. SMLM images of tau in Clone 4.1 (Fig. 2.2A and
additional representative examples in SI Appendix A, Fig. A6) were dramatically different
from those of Clone 4.0 (Fig. 2.1A and SI Appendix A, Fig. A2A). While a small population
of microtubule-associated tau remained, there was a large population of cytosolic tau
aggregates having diverse sizes and shapes.
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The resulting Voronoi-segmented objects ranged from small nanoclusters, similar to those
observed in nonaggregated tau cell models and neurons, to fibrillary structures and large
conglomerate aggregates that are reminiscent of NFTs in terms of their size (Fig. 2.2A).
The number of localizations per segmented object (Fig. 2.2B) and the area of the
segmented objects (SI Appendix A, Fig. A5B) were very broad and on average higher
compared to the nanoclusters in Clone 4.0, in line with the visual impression of the
presence of a wide range of aggregate structures.

Figure 2.2: Tau oligomers in cells harboring tau aggregates are distinct from tau oligomers in cells
modeling a nonaggregated tau state.
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A. Super-resolution image of tau in Clone 4.1 cells maintained in Dox and expressing 4R-P301LGFP tau. Zoomed in regions after Voronoi segmentation are shown. Segmented images are
pseudo color coded with different colors corresponding to different segmented objects.
Nanoclusters (magenta circles), fibrillary structures (green circles), branched fibrils (yellow circles),
and conglomerate NFT-like structures (white circles) are visible in the segmented images. B. Violin
plots showing the number of localizations per Voronoi-segmented tau nanocluster in Clone 4.0 cells
expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression (green) and
Voronoi-segmented tau object in Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP
tau (pink). The dashed lines indicate the median, and the dotted lines indicate the 25th and 75th
percentile (Clone 4.0: n = 15 cells, n = 3 experiments; Clone 4.1: n = 20 cells, n = 3 experiments).
****P < 0.0001. C. Two-color super-resolution images of α-tubulin (magenta), total tau (cyan), and
overlay in Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP tau. The results of the
colocalization analysis are shown in which tau aggregates colocalized with α-tubulin are color
coded in magenta, and isolated aggregates are shown in yellow. D. Two-color super-resolution
images of oligomeric tau detected by tau oligomer-specific T22 antibody (magenta), total tau (cyan),
and overlay in Clone 4.1 maintained in Dox and expressing 4R-P301L-GFP tau. The results of the
colocalization analysis are shown in which tau aggregates colocalized with T22 are color coded in
magenta, and isolated aggregates are shown in yellow. E. Violin plots showing the number of
localizations per Voronoi-segmented tau nanocluster that colocalizes with α-tubulin in Clones 4.0
cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression (green) and
Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP tau (pink). The dashed lines
indicate the median and the dotted lines indicate the 25th and 75th percentile (4.0: n = 9 cells, n =
2 experiments; 4.1: n = 7 cells, n = 2 experiments). ****P < 0.0001.

To once again determine the percentage of oligomeric tau and the amount of cytosolic
versus microtubule-associated tau present in these aggregated tau cells, we performed
two-color SMLM. We labeled tau together with α-tubulin (Fig. 2.2C) or with T22 (Fig. 2.2D)
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and performed the colocalization analysis. The percentage of microtubule-associated tau
in Clone 4.1 (∼10 ± 9% uncorrected or ∼17% corrected based on the colocalization
positive control) was significantly lower than that in Clone 4.0 (∼61% uncorrected and
100% corrected) (Fig. 2.1G). However, similar to Clone 4.0, ∼20 ± 9% of tau (∼34%
corrected) colocalized with the oligomeric T22 antibody (Fig. 2.1G). The large tau
aggregates reminiscent of neurofibrillary tangles were clearly excluded from microtubules
and also did not colocalize with T22 (Fig. 2.2 C and D). The number of localizations per
microtubule-associated tau object was higher in Clone 4.1 than that for the nanoclusters
in Clone 4.0, suggesting that there are small tau aggregates that remain on the
microtubule (Fig. 2.2E). To further confirm this result, we next used the calibration
approach to determine the copy number composition of the oligomeric tau species in
Clone 4.1 by fitting the distribution of the number of localizations to the calibration function
obtained from the nanobody dilution experiment (SI Appendix A, Fig. A5C). The
distribution of the number of localizations for Clone 4.1 is highly skewed with a long tail
corresponding to the presence of a diverse range of large aggregates containing a high
number of localizations. We therefore focused on fitting the part of the curve
corresponding to smaller aggregates, including nanoclusters and small fibrils. This
analysis showed that the copy number of tau within these small aggregates ranged
between one to seven tau molecules. Interestingly, the percentage of monomeric tau was
similar in Clone 4.0 and Clone 4.1, whereas the percentage of dimers and trimers
decreased, and the percentage of higher-order oligomers increased in Clone 4.1
compared to Clone 4.0. These results suggest that the dimers and trimers may seed the
formation of the higher-order oligomers consisting of greater than three tau proteins during
tau aggregation.
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We next asked if tau aggregation had any impact on the integrity of the microtubule
network. To address this question, we imaged the microtubule network in Clone 4.1 cells
using SMLM. Surprisingly, tau aggregation led to a disruption of the microtubule network,
leading to significantly less dense microtubules in Clone 4.1 compared to Clone 4.0 both
with (+Dox) and without (−Dox) tau (SI Appendix A, Fig. A1 C and D, Bottom, third plot).
This finding suggests that tau aggregates have an adverse effect on the microtubule
network integrity. Overall, our results show the presence of oligomers consisting of greater
than three tau proteins in cells harboring tau aggregates that are not present under
nonaggregated conditions and that remain partially microtubule associated, in addition to
a diverse range of larger tau aggregates that together disrupt the integrity of the
microtubule network in a cell model of FTDP-17.

Discussion
By using cell models in which tau is either predominantly microtubule associated or tau is
aggregated, we demonstrated using super-resolution microscopy that tau forms small
oligomers—mostly dimers and trimers—on microtubules, which are distinct from tau
aggregates. The distribution of tau on microtubules in cell models representing the
nonaggregated state of tau (BSC-1 cells expressing 3R-WT-GFP tau and 4R-WT-GFP tau
as well as QBI-293 Clone 4.0 cells expressing 4R-P301L-GFP tau) and in hippocampal
neurons is not uniform, but instead, we showed that tau forms nanoclusters. Previous AFM
and other in vitro studies have shown that P301L tau isolated from yeast (Vandebroek et
al. 2006) and WT tau from rat (Makrides et al. 2003) form tau clusters and oligomers on
taxol-stabilized microtubules, respectively. Furthermore, these previous studies showed
that P301L tau causes microtubules to stick together and bend abnormally, which was not
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the case for WT tau (Vandebroek et al. 2006). However, in the context of human tau
expressed in mammalian cells and endogenous tau in neurons, we did not observe such
microtubule abnormalities, and both WT and P301L tau formed nanoclusters.

Most recently, in vitro studies described the formation of physiological tau condensates
(R. Tan et al. 2019) also called tau “cohesive islands” (Siahaan et al. 2019) on
microtubules. In both cases, these tau structures were shown to undergo liquid–liquid
phase separation, and the size of the condensates was in the micrometer range. The
nanoclusters we observe are much smaller than these liquid condensates that form in
vitro; instead, microtubule-associated tau inside cells mainly consists of small tau
complexes including monomers, dimers, and trimers. Historically, tau oligomerization has
been mostly deemed a pathological feature of tau. However, our findings show that
endogenous tau can form small oligomers under physiological conditions in neurons. It
has been speculated that an electrostatic zipper resulting from anti-parallel alignment of
N-terminal halves of two tau molecules may be mediating tau dimerization (Rosenberg et
al. 2008). Since tau is a highly disordered protein, it would be interesting to explore how it
could form oligomers on microtubules.

Future studies exploring the relationship between different tau isoforms/mutants and
oligomer formation as well as investigating whether tau isoforms/mutants that do not form
oligomers are resistant to aggregation would bring exciting new insights into the
mechanisms of physiological and pathological tau oligomerization. From an evolutionary
point of view, protein dimerization/oligomerization is a commonly used mechanism of
functional regulation for many proteins, as it promotes protein complex formation in
physiological settings rather than just in pathology (Marianayagam, Sunde, and Matthews
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2004). Our findings therefore bring up interesting questions regarding the physiological
function of tau oligomers, which should be subject of future studies. They can potentially
mediate microtubule bundling as well as interact with and regulate the function of
microtubule motors and severing enzymes as suggested in previous in vitro studies (Dixit
et al. 2008) (R. Tan et al. 2019) (Siahaan et al. 2019).

Introducing tau oligomers into the brain of WT rodents has resulted in synaptic and
memory dysfunction, supporting the hypothesis that tau oligomers are toxic (Fá et al.
2016) (Ondrejcak et al. 2018). Moreover, introducing tau oligomers directly into
mammalian neurons using patch clamp electrodes also modified synaptic transmission
and blocked events that could be underlying memory storage (Hill et al. 2019).
Overexpression of human tau in a mouse N2A cell model also led to the formation of tau
oligomers, which could be detected with immuno-electron microscopy and superresolution microscopy as clusters associated to the plasma membrane (Merezhko et al.
2018). These tau clusters were shown to be secreted via an unconventional secretion
pathway (Merezhko et al. 2018). Hence, tau oligomers likely also play an important role in
propagation of tau pathology between neuronal cells. Here, we showed that in cells in
which tau has undergone aggregation, the proportion of tau monomers was similar to cells
lacking tau aggregation, but the proportion of dimers/trimers decreased, and higher-order
oligomers appeared. This result, taken together with the result that tau forms small
oligomers in hippocampal neurons, suggests that there is a distinction between small
physiological tau oligomers and larger pathological tau oligomers.

Previous in vitro aggregation studies showed that tau dimers are the basic subunit of
higher-order tau oligomers (Feinstein et al. 2016) and that tau dimerization is one
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important rate-limiting step in the progression of tau aggregation (Friedhoff et al. 1998).
These results are in line with our work, but here, we further demonstrate that tau
dimers/trimers exist on microtubules prior to tau aggregation and therefore may be primed
to template further aggregation in disease.

We showed that the majority of tau aggregates were excluded from microtubules.
However, a small population of aggregated tau was found associated with microtubules,
further suggesting that aggregation could be initiated from dimers/trimers present on
microtubules. We further showed that tau aggregation negatively impacted the
microtubule network itself. The density of the remaining microtubules in Clone 4.1 cells
was lower than the basal conditions in Clone 4.0 cells (i.e., before the induction of tau
aggregation). These results suggest that it is not just the dissociation of tau from the
microtubule but the formation of tau aggregates that leads to microtubule disruption. It
would be interesting to explore the mechanisms that lead to this microtubule network
disruption and whether a specific tau aggregate species (oligomers or larger aggregates)
leads to toxicity and the loss of microtubule integrity.

Overall, we present an approach based on super-resolution microscopy and quantitative
analysis to characterize the distribution of tau in intact cells with nanoscale spatial
resolution. Our approach opens the door for studying the mechanisms and kinetics of tau
aggregation in vivo, the presence of early tau aggregates including pathological oligomers
in disease, and screening for drugs that can potentially target and disrupt these
pathological oligomers.
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Materials and Methods
A detailed description of the methods can be found in SI Appendix A. Briefly, a stable cell
line expressing 3R-WT-GFP tau was derived from African green monkey (Cercopithecus
aethiops) kidney epithelial cells (BSC-1; CCL-26; American Type Culture Collection). For
some experiments, BSC-1 cells were transfected with either a 4R-WT-GFP tau construct
or a 4R-WT tau construct to transiently express tau (SI Appendix, Figs. S1A, S2B, and
S3 G and H). In addition, two stable human embryonic kidney-derived QBI-293 cell lines
(Clone 4.0, Clone 4.1) expressing full-length human tau T40 (2N4R or 4R) carrying the
P301L mutation with a GFP tag, a kind gift from the V. Lee laboratory at the University of
Pennsylvania, Philadelphia, PA, were used for experiments. Clone 4.1 is sorted from
Clone 4.0 cells to enrich for large, compact tau aggregates after exogenous tau fibril
addition. Clone 4.0 was cultured in Dox overnight (16 to 24 h) prior to fixation unless
otherwise stated (reference SI Appendix A, Fig. A3I for different Dox timing experiments),
whereas Clone 4.1 was maintained in Dox continuously. E18 Sprague Dawley rat
hippocampal neurons were obtained in suspension from the Neuron Culture Service
Center at the University of Pennsylvania. Cells were grown on chambered coverglass,
fixed with ice cold methanol, and immunostained with appropriate antibodies prior to
super-resolution microscopy using a Nanoimager from Oxford Nanoimaging.
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CHAPTER 3. PHOSPHORYLATION OF SPECIFIC TAU RESIDUES IS
ASSOCIATED WITH DIFFERENT TYPES OF HIGHER ORDER TAU
AGGREGATE CLASSES
Adapted from article published as: Gyparaki, M. T., Arab, A., Sorokina, E. M., SantiagoRuiz, A. N., Bohrer, C. H., Xiao, J. and Lakadamyali, M. (2021). Tau forms oligomeric
complexes on microtubules that are distinct from tau aggregates. PNAS, 118,
e2021461118 (19). PNAS authors do not need permission to include their articles as part
of their dissertation.
Introduction

Tau is a microtubule-associated protein whose activity is regulated by the degree of its
phosphorylation and is otherwise known as a phosphoprotein (Lindwall and Cole 1984)
(Alonso et al. 1994). Tau found in the human brain normally contains 2-3 moles of
phosphate per 1 mole of tau protein, an amount found to be optimal for tau’s association
with microtubules and its role in promoting microtubule assembly (Kopke et al. 1993).
Almost all tau is soluble in normal brain, whereas in AD brain tau exists in soluble
oligomeric and insoluble fibrillized forms (Kopke et al. 1993) (Grundke-Iqbal et al. 1986)
(Bancher et al. 1989). Even though the amount of soluble tau is similar in normal and AD
brain, the amount of total tau is significantly increased in AD brain almost entirely due to
the presence of abnormally hyperphosphorylated tau (Khatoon, Grundke‐Iqbal, and Iqbal
1992). Phosphorylation levels of tau increase by 3-4 fold (8 moles of phosphate per mole
of tau) when tau becomes hyperphoshorylated (Kopke et al. 1993). Up to 40% of the
abnormally hyperphosphorylated tau exists in the cytosol and is not part of PHFs or NFTs
(Kopke et al. 1993) (Grundke-Iqbal et al. 1986) (Bancher et al. 1989). Moreover, this
abnormally hyperphosphorylated tau is disruptive to microtubules and inhibits their
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assembly (Alonso et al. 1994) (B. Li et al. 2007). Phosphorylation-specific tau antibodies,
such as AT8 targeting Ser202/Thr205, have been useful in tracking the progression of tau
pathology. Most AD human postmortem brain tissue staging is consistent with the Braak
staging scheme where NFTs containing hyperphosphorylated tau are found in the
transentorhinal region in stages I-II, then in limbic regions such as the hippocampus and
stages III-IV and finally in the general neocortex area during stages V-VI. In later stages,
other phosphorylation sites emerge (H. Braak and Braak 1991) (Heiko Braak et al. 2006).
It is very possible that differences in tau phosphorylation sites could lead to the
development of different tau strains differentiating tauopathies but also adding
heterogeneity within the same disease.
Here, we have used quantitative super-resolution microscopy in combination with an
unsupervised machine learning-based shape classification approach we developed to
study the different tau aggregate species present in an engineered cell model expressing
tau harboring the FTDP-17 mutation P301L and transduced with exogenous tau fibrils to
mimic tau aggregation in disease (QBI-293 Clone 4.1 cells expressing 4R-P301L-GFP
tau). Using antibodies that recognize different phosphorylation states of tau and our shape
classification method, we further show that different phosphorylation states associate with
distinct higher-order tau aggregate species in this engineered cell model.
Results

Iterative Hierarchical Clustering Identifies the Presence of Distinct Tau Aggregate
Classes.

To further investigate the types of higher-order tau aggregates present in Clone 4.1 cells,
we developed an unsupervised shape classification algorithm based on iterative
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hierarchical clustering to classify the large tau aggregates present in SMLM images (SI
Appendix B, Materials and Methods and Fig. B1A–F). We named the algorithm Iterative
Hierarchical Clustering c-RSD (constrained relative SD). We first visually separated Clone
4.1 cells into two categories: those showing a low level of tau aggregation containing
mainly small tau aggregates and those showing a high level of tau aggregation containing
larger tau aggregates. The SMLM images from these two categories were then segmented
into individual tau aggregates using density-based spatial clustering of applications with
noise (DBSCAN) (Ester et al. 1996) (SI Appendix B, Materials and Methods). We focused
on tau aggregates containing more than 500 localizations. This choice was due to the fact
that aggregates with fewer localizations than 500 represented a uniform class of
nanoclusters with no particular shape and likely corresponded to tau oligomers (SI
Appendix B, Fig. B1C) (∼2.5% of all segmented objects had >500 localizations in Clone
4.1 cells). DBSCAN segmentation of images from Clone 4.0 cells gave rise to very few
segmented objects containing >500 localizations (∼0.12% of all segmented objects had
>500 localizations in Clone 4.0 cells), further confirming that these objects correspond to
tau aggregates not present in cells lacking tau aggregation. The tau aggregates coming
from cells with low and high tau aggregation levels were combined into a single list and
further classified with Iterative Hierarchical Clustering c-RSD. The number of localizations
per tau aggregate, tau aggregate area, length, and width were used as classification
parameters. We imposed a threshold for the coefficient of variation for each parameter
and grouped the tau aggregates together into individual classes as long as the coefficient
of variation in the parameters did not exceed the imposed threshold (i.e., the tau
aggregates within each class were “self-similar” within the imposed threshold) (SI
Appendix B, Materials and Methods).
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Smaller variation thresholds result in a larger number of identified classes from the
classification scheme. We selected the threshold such that the classification was more
sensitive to aggregate length and width (i.e., aggregate shape) than the number of
localizations and area.

Table S.3.1 contains the number of tau aggregates that were segmented before
classification and the resulting number of classes after classification. The classes were
represented in the form of a dendrogram tree (SI Appendix B, Fig. B1D). The initial
classification tended to overestimate the number of classes and tau aggregates that were
visually self-similar were classified as distinct classes. Thus, we further narrowed them
down by combining classes that were close in the dendrogram tree and visually looked
similar to each other (SI Appendix B, Table S.3.1 and Fig. B1 D–F). This classification
generated 22 classes containing tau aggregates coming from cells with both low and high
levels of tau aggregation. These classes contained tau aggregates ranging in area by
three orders of magnitudes (from 0.025 µm2 for the smallest classes to 30 µm2 for the
largest ones). The presence of as many as 22 classes of tau aggregates suggests that
the tau aggregates found in Clone 4.1 cells are highly diverse in terms of their size and
shape.

We plotted the results in the form of an ellipse graph in which each ellipse corresponds to
a specific tau aggregate class (Fig. 3.1 A–J). The size of the ellipse corresponds to the
percentage of total tau aggregates from cells with low or high levels of tau aggregation in
that particular class (SI Appendix B, Table S.3.2), whereas the shape of the ellipse
represents the shape of the aggregates in that particular class (i.e., more elongated
ellipses correspond to elongated aggregates with high aspect ratio). Visual inspection of
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aggregates within specific classes revealed linear tau fibrils (e.g., class 6, Fig. 3.1D),
branched tau fibrils (e.g., classes 9 and 10, Fig. 3.1E), NFT pretangle-like structures (e.g.,
classes 12 and 15, Fig. 3.1I) as well as large agglomerate structures resembling NFTs
(e.g., classes 21 and 22, Fig. 3.1J). These different classes may represent different stages
of tau aggregation or different aggregation pathways. There was a large overlap in terms
of the tau aggregate classes found in cells with low and high levels of tau aggregation.
Linear and branched tau fibrils constituted the majority of tau aggregate classes in both
cases. However, there were also some unique classes that were only present in cells with
high levels of tau aggregation (Fig. 3.1 H and J and SI Appendix B, Table S.3.2). In
particular, classes having large areas and a large number of localizations that resembled
NFT-like structures (e.g., classes 21 and 22) were only found in cells with high levels of
tau aggregation, whereas small tau fibrils (e.g., class 6) were more representative of cells
with low levels of tau aggregation.
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Figure 3.1: Shape classification reveals distinct classes of tau aggregates in Clone 4.1 cells.
A–C and F–H. Ellipse plots showing the different tau classes found in Clone 4.1 cells
maintained in Dox and expressing 4R-P301L-GFP tau. They are showing either low (green) or
high (magenta) levels of tau aggregation. Each ellipse represents a separate class. The plot
axes represent the number of localizations per tau aggregate and area of tau aggregates in
square micrometer. Each ellipse is placed on the plot to represent the average number of
localizations and area of the tau aggregates within that class. The size of the ellipses is scaled
within each plot to represent the proportion of tau aggregates contained in that particular class,
but the size is not comparable between the different plots. Green repre sents the proportion of
tau aggregates from low tau aggregation cells, whereas magenta represents the proportion of
tau aggregates from high tau aggregation cells. The bar charts next to the ellipse plots
represent the percentage of tau aggregates from each category (low in green and high in
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magenta) found in classes in the specified number of localizations and area range. Ellipses
represent average numbers, not extreme outliers. D, E, I, and J. Representative superresolution images of tau aggregates from some of the most prominent classes in each plot.
Shapes from cells showing low levels of tau aggregation are colored green, whereas those
from cells showing high levels of tau aggregation cells are colored magenta. (Scale bars: 500
nm.)

Phosphorylation of Specific Tau Residues Is Associated with Different Types of
Higher-Order Tau Aggregates.
Iterative Hierarchical Clustering c-RSD revealed the presence of a diverse range of tau
aggregates (Fig. 3.1 A–J). However, the nature of tau present within these aggregates is
unclear. In order to investigate the phosphorylation state of tau within these aggregate
species, we performed two-color SMLM using two commonly used phospho-tau
antibodies, Thr231 and AT8, which are known to have high labeling specificity (D. Li and
Cho 2020). Thr231 targets tau that is phosphorylated at the 231st threonine, which is
considered to be an early marker of tau aggregation. AT8 targets tau that is
phosphorylated at the serine residue at position 202 and threonine at position 205
(Ser202/Thr205), which is considered to be a late marker of tau aggregation. Staining with
both antibodies gave rise to a low, nonspecific, fluorescent signal in Clone 4.0 cells
compared to Clone 4.1 cells (SI Appendix B, Fig. B2 A and B), indicating that tau present
in Clone 4.0 cell line is not hyper-phosphorylated at any of the targeted residues (Matsuo
et al. 1994). This result is in line with the expectation that hyper-phosphorylation of these
residues is a marker of pathological tau aggregation and further supports that Clone 4.1
cells exhibit common markers of tau pathology found in disease. Single-color (Fig.
3.2 A and B and additional representative images in SI Appendix B, Fig. B3 A and B) and
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two-color (SI Appendix B, Fig. B3 C and D) SMLM images of Clone 4.1 cells with either
the Thr231 or the AT8 antibodies revealed that both antibodies bind to a wide range of tau
aggregates having diverse shapes and sizes. Only ∼12 ± 10% (∼20% corrected) of GFP
tau found within Clone 4.1 cells colocalized with either Thr231 or AT8 (Fig. 3.2C),
suggesting that aggregation in this cell model can potentially proceed in the absence of
hyperphosphorylation of these particular tau epitopes. The number of localizations per tau
aggregate detected by the two antibodies was similar, suggesting that there is overlap in
the tau aggregates that these antibodies target (SI Appendix B, Fig. B3E).
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Figure 3.2: Branched tau fibrils and long tau fibrils are the predominant tau structures
recognized by Thr231 and AT8 antibodies, respectively. A. Super-resolution image of tau
labeled with the Thr231 antibody in Clone 4.1 cells maintained in Dox and expressing 4R P301L-GFP tau. Zoomed-in regions after Voronoi segmentation are shown. Segmented images
are pseudo color coded with different colors corresponding to different segmented objects.
Yellow circles highlight branched tau fibril-like structures. B. Super-resolution image of tau
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labeled with AT8 antibody in QBI cells, Clone 4.1, expressing 4R -P301L-GFP tau. Zoomed in
regions after Voronoi segmentation are shown. Segmented images are pseudo color coded
with different colors corresponding to different segmented objects. Yellow circles highlight long
tau fibril-like structures. C. Violin plots showing the percentage of tau nanoc lusters colocalized
with Thr231, and AT8 antibodies in Clone 4.1 cells maintained in Dox and expressing 4R P301L-GFP tau (pink). (Thr231 in Clone 4.1: n = 6 cells, n = 2 experiments; and AT8 in Clone
4.1: n = 6 cells, n = 3 experiments)

To further investigate whether different tau aggregates have differential phosphorylation
states, we classified tau aggregates from Clone 4.1 cells stained with either the GFP
nanobody or the Thr231 or AT8 antibody using Iterative Hierarchical Clustering c-RSD.
We obtained 23 classes, very similar to the number of classes obtained from classifying
the GFP nanobody-labeled aggregates in cells having low or high levels of tau aggregation
(SI Appendix B, Table S.3.2). As expected, there was large overlap in the tau aggregate
classes stained with the Thr231, AT8, and GFP nanobody (Fig. 3.3 A–J). However, tau
aggregates from cells stained with Thr231, which is an earlier tau aggregation marker,
were over-represented by approximately twofold in class 3, corresponding to small,
branched tau fibrils (Fig. 3.3E and SI Appendix B, Table S.3.3) compared to AT8 or the
GFP nanobody. It is therefore possible that phosphorylation at this residue is a
characteristic of small, branched tau fibrils. Similarly, AT8-labeled tau aggregates were
over-represented by approximately two- to fourfold in classes 4 and 5, corresponding to
long linear fibrillary structures, suggesting that phosphorylation at Ser202/Thr205 may be
a prominent feature of this class of tau aggregates (Fig. 3.3D and SI Appendix B, Table
S.3.3). Furthermore, there were unique classes resembling NFT pretangle-like and NFTlike structures, which were only present in cells stained with the late tau aggregation
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marker AT8 but not the early tau aggregation marker Thr231 (Fig. 3.3 F–J and SI
Appendix B, Table S.3.3). It is possible that the phosphorylated Thr231 epitope is not
accessible to the antibody within these large aggregates. However, it is also possible that
not all tau aggregates acquire this phosphorylation mark.

Figure

3.3:

Shape

classification

differentiates

higher-order

aggregates

based

on

phosphorylation status. A–C and F–H. Ellipse plots showing the different tau classes found in
Thr231- (magenta), AT8- (green), or GFP nanobody- (blue) labeled Clone 4.1 cells maintained
in Dox and expressing 4R-P301L-GFP tau. Ellipse representation is the same as in Fig. 3.1.
D, E, I, and J. Representative super-resolution images of tau aggregates from some of the
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most prominent classes in each plot. Shapes from Thr231-stained cells are colored magenta,
those from AT8-stained cells are colored green, and those from the GFP nanobody staining
are colored blue. N/A indicates not available. (Scale bars: 500 nm.)

Discussion
In this work, we showed that oligomers in cells that represent a nonaggregated state of
tau are not hyperphosphorylated at residues Thr231 and Ser202 and Thr205, but
oligomers in cells that represent an aggregated state of tau contain these phosphorylation
markers, suggesting that physiological oligomers are distinct from pathological oligomers.
Hyperphosphorylation of tau has been considered a prerequisite for tau aggregation since
the negative charge of phosphor residues neutralizes the positively charged microtubulebinding region of tau, leading to tau’s dissociation from the microtubules and eventual
aggregation (Maeda et al. 2007). However, tau oligomerization can occur without
hyperphosphorylation or the addition of inducers, suggesting that hyperphosphorylation of
tau in vivo could be important for dissociation from microtubules but may not be necessary
for the aggregation step (Hill et al. 2019). Additionally, biochemical studies have shown
that tau oligomers are most likely hetero-oligomers of nonhyperphosphorylated and
hyperphosphorylated tau (Kopke et al. 1993). Hence, it is possible that tau aggregation
can start on the microtubule before tau dissociation due to hyperphosphorylation. In the
future, it would be interesting to study the kinetics of pathological tau aggregation over
time to directly test this model.

Phosphorylation at Thr231 is an early aggregation event which diminishes the ability of
tau to bind to microtubules and is often used as a marker for postmortem diagnosis of
most tauopathies (Cho and Johnson 2003). Phosphorylation at Ser202 and Thr205 is a
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marker of late-stage aggregation and is also used for postmortem diagnosis of tauopathies
(Kimura et al. 2018). Here, we show that phosphor-tau antibodies that recognize these
different phosphorylation sites label a subset of tau aggregates, suggesting that tau
aggregation can proceed in the absence of phosphorylation at these residues.
Furthermore, using Iterative Hierarchical Clustering c-RSD, we classified the tau
aggregates containing these specific phosphorylation marks. The resulting classification
identified a variety of distinct classes of tau aggregates that could be grouped into four
general categories: tau fibrils, branched tau fibrils, NFT pretangle-like tau aggregates, and
NFT-like tau aggregates. There was an overlap in the classes stained by the
nanobody/antibodies, but there were also classes that were more prominently recognized
by either the Thr231 or the AT8 antibodies. These results suggest that phosphorylation at
certain residues may be a characteristic of distinct types of tau aggregates.

In recent years, the idea of tau strains with distinct structural conformations has become
prevalent (Kimura et al. 2018) (Prusiner 1984). In particular, it has been found that different
tauopathies are associated with disease-specific tau protofilaments (Fitzpatrick et al.
2017) (Sanders et al. 2014) (Falcon et al. 2018) (Falcon et al. 2019) (W. Zhang et al.
2019b). Recent cryo-EM work in combination with mass spectrometry–based proteomics
revealed that posttranslational modifications (PTMs) of tau such as ubiquitination can
mediate interprotofilament interfaces (Arakhamia et al. 2020). Based on these results, a
structure-based model has been proposed in which cross-talk between tau PTMs
influences tau filament structure, leading to diversity of tauopathy-specific tau strains
(Arakhamia et al. 2020).
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It is possible that some of the different classes of tau aggregates we detected in our FTDP17 model are propagated by the different tau strains and that differences in tau filament
structure identified in cryo-EM lead to different higher-order tau aggregate classes
identified in super-resolution microscopy, an idea reinforced by the finding that the
phosphorylation state of tau is distinct in certain tau aggregate classes. It would be
interesting in the future to determine whether different MAPT mutations and different tau
PTMs associated with tauopathies, including acetylation, phosphorylation, and
ubiquitination (Alquezar, Arya, and Kao 2021), lead to different tau aggregates. A
combination of super-resolution microscopy and cryo-EM can in the future reveal
differences in tau filament structure of different classes of higher-order tau aggregates.

Here, using super-resolution microscopy and a shape classification method, we showed
that tau aggregate species could have distinct phosphorylation marker profiles which could
lead to the formation of distinct tau strains. Our custom algorithm, Iterative Hierarchical
Clustering c-RSD, will be a useful tool for differentiating between tau aggregates
associated with different tau strains in the future and could facilitate the study and
identification of tau strains in vitro and in vivo.

Materials and Methods
A detailed description of the methods can be found in SI Appendix B.
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CHAPTER 4. DISTINCT TAU AGGREGATE SPECIES BECOME DEGRADED
BY THE UBIQUITIN-PROTEASOME SYSTEM AND AUTOPHAGY

Introduction
Tauopathies are characterized by the abnormal accumulation of tau aggregates, which
are not properly degraded by the cell’s main degradation pathways of autophagy and the
ubiquitin-proteasome system (UPS). More specifically, UPS involves degradation by the
20S proteasome, which is the proteolytic core of the 26S holoenzyme (Bochtler et al.
1999). Intrinsically disordered proteins (IDPs) such as soluble tau can also be degraded
just by the 20S proteasome without the need of the 19S regulatory subunit (David et al.
2002). Phosphorylation and aggregation of tau can inhibit its degradation by the 20S
subunit (Poppek et al. 2006). Hyperphosphorylated, insoluble tau aggregates are
traditionally thought to be degraded by autophagy instead (Cheng et al. 2018). Yet, the
presence of accumulated lysosomes, autolysosomes, autophagosomes as well as
defective lysosomal membranes in the brains of AD, CBD and PSP patients indicates
defective autophagic activity (Nixon et al. 2005) (Nixon 2013) (Piras et al. 2016). In fact,
excess of tau aggregates is indeed thought to have a negative impact on UPS and/or
autophagy, inhibiting these pathways inside neurons. Along similar lines, pharmacological
inhibition of these pathways can result in the accumulation of tau aggregates (J. L. Guo et
al. 2016). Previously, using super-resolution microscopy and machine learning based
shape classification (see Chapter 3), we showed that tau aggregates form a
morphologically diverse class consisting of tau oligomers, linear fibrils, branched fibrils,
NFT Precursor-like and NFT-like species. However, the physical nature of the tau
aggregates which can be cleared by UPS or autophagy pathways as well as the physical
nature of tau aggregates that accumulate as a result of dysfunctional clearance
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mechanisms has not been elucidated. Understanding the nature of such aggregate
species could have important therapeutic implications.
Here, using super-resolution imaging and computational analysis, we have now extended
our previous work in the aggregated tau cell line, QBI-293 Clone 4.1 cells expressing 4RP301L-GFP tau to determine i) the timing of tau aggregate clearance upon removal of
soluble tau, and ii) the morphological characteristics of tau aggregate species degraded
by autophagy and/or UPS.
Results

Tau protein and tau aggregate density gradually decrease following the removal of
soluble tau

To examine the process of tau aggregate degradation, we performed single molecule
localization microscopy (SMLM) in an engineered cell model of tau aggregation consisting
of an inducible QBI-293 cell line stably expressing GFP-tagged tau harboring a FTDP-17
mutation (P301L) under the control of doxycycline (Dox) (QBI-293 Clone 4.1 cells
expressing 4R-P301L-GFP tau). Removal of Dox from the culture media ceases
expression of the soluble tau construct. Previous work (J. L. Guo et al. 2016) showed that
removal of dox led to a decrease in the tau aggregate amount by using Western Blot
analysis of the Triton-insoluble fraction. The decrease in tau aggregates was not a result
of dilution due to cell division as whole coverslip quantification of Triton-insoluble
aggregates in cells plated at 5 days off dox and analyzed at 7 and 10 days off dox without
any further passaging showed a similar decrease in total tau aggregate intensity (J. L. Guo
et al. 2016). To get a deeper insight into the physical nature of tau aggregates cleared
upon dox removal in this cell model, we used SMLM imaging of cells fixed at several time
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points after dox removal. The SMLM results recapitulated the previous findings
demonstrating a decrease in tau aggregates over time (Fig. 4.1A, SI Appendix C, Fig.
C1A-G). A quantitative analysis of the localizations corresponding to tau proteins in our
images revealed a gradual decrease in tau protein density upon Dox removal compared
to the +dox control, where cells are kept in media containing Dox (Fig. 4.1B). More
specifically, the most significant decrease in tau protein density starts on day 3 off dox
(median: 0.0002361) compared to the +dox control (median: 0.0007115) (a 3-fold
decrease) and the next major drop is on day 10 off dox (0.00004606) (a 15-fold decrease)
(Fig. 4.1B, C). These results are consistent with tau aggregate degradation shown in
previous studies (J. L. Guo et al. 2016) and inconsistent with cell division mediated
aggregate dilution, where a gradual 2-fold decrease is expected per day as cells divide.

Figure 4.1: Tau aggregate density decreases in the absence of soluble tau. A. SMLM images of
tau in the FTDP-17 cell model, where doxycycline (dox), which controls the expression of the
soluble tau construct has been removed from the media for several days. Scale bar in inset is 1μm.
B, C. Plots of the total localization density (proportional to tau protein density) (B) and median fold
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change in the localization density (C) of tau proteins in cells exhibiting tau aggregation under +dox
and various days following dox removal. Plots represent three biological replicates (different
colored means in B). Fold change is calculated with respect to +dox. D. Segmented images of tau
clusters with less than 500 localizations (locs). E. Segmented images of tau clusters with more than
500 localizations (locs). Different clusters are pseudocolored. Scale bar for insets is 2 μm. F.
Median fold change plots of the number of clusters with less than 500 localizations normalized to
the cell area in cells exhibiting tau aggregation either with +dox or day 1, 2, 3, 4, 5 or 10 after dox
removal. Fold change is calculated with respect to +dox. G. Plots of the number of clusters with
more than 500 localizations normalized to the cell area in cells exhibiting tau aggregation either on
day 0 or day 1, 2, 3, 4, 5 or 10 after dox removal. Error bars indicate standard deviation (SD). +dox
control: n= 29 cells, n= 3 experiments, Day 1 off dox: n= 27 cells, n= 3 experiments, Day 2 off dox:
n= 30 cells, n= 3 experiments, Day 3 off dox: n= 27 cells, n= 3 experiments, Day 4 off dox: n= 29
cells, n= 3 experiments, Day 5 off dox: n= 27 cells, n= 3 experiments, Day 10 off dox: n= 28 cells,
n= 3 experiments, * P<0.05, ** P<0.001, ****P < 0.0001.

Visual inspection of images showed that large tau aggregates resembling NFTs seem
smaller in size and their presence becomes less frequent in images from later days off
dox (SI Appendix C, Fig. C1A-G). As we previously showed (see Chapter 2), tau
aggregates in Clone 4.1 cells are mainly cytosolic and only a small percentage of small,
oligomeric tau is microtubule-associated. Interestingly, a pattern resembling microtubuleassociated tau similar to Clone 4.0 cells (non-aggregated cell model) re-appears on day
5 off dox in some cells and persists at later time points (Fig. 4.1A). On day 10 off dox,
almost all tau is microtubule-associated and large tau aggregate structures are rarely
observed. These results are also inconsistent with cell division mediated dilution, in which
we would expect to have similar aggregates over time but with reduced numbers per cell
area.
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To get better insight into the clearance dynamics of the small tau aggregates compared
to large tau aggregate species, we used the Voronoi tessellation approach to cluster and
segment individual tau aggregates (Fig. 4.1D, E). We then divided the segmented tau
aggregates into two categories, aggregates with less than 500 localizations, which we
previously showed mainly correspond to tau oligomers/small fibrils and those containing
more than 500 localizations, which mainly correspond to insoluble tau aggregates
including large linear and branched fibrils and NFTs. We determined the number of tau
aggregates belonging to each category and normalized this number with cell area to
calculate how tau oligomer and insoluble aggregate density changes over time upon Dox
removal. Interestingly, the density of tau aggregates with less than 500 localizations (likely
corresponding to tau oligomers) is relatively consistent from +dox to day 1 and 2 off dox,
drops at day 3 off dox and maintains similar levels until day 10 off dox (Fig. 4.1F). The
density of large and insoluble tau aggregates containing more than 500 localizations also
drops on day 3 off dox but continues to decrease over time with the next major drop
happening at 10 days off dox (Fig. 4.1G). These results suggest that small tau aggregates
(oligomers, small fibrils) are degraded first while the larger tau aggregates take longer time
to clear and continue to be degraded until later days off dox. Alternative interpretation of
these results could be that large aggregates become split up into smaller units (oligomers,
small fibrils) at later time points and these smaller aggregates are then cleared. Breaking
apart of the larger aggregates into smaller oligomers (<500 localizations) would lead to an
increase in this small aggregate density and the simultaneous clearance of these small
aggregates would then balance out the increase potentially resulting in constant levels of
small aggregates present throughout the later days of dox removal.
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Pre-NFTs and NFTs are more efficiently cleared upon Dox removal compared to
linear fibrils.

Next, we aimed to examine more closely which tau aggregate species become degraded
during the dox removal process. In particular, we focused on large tau aggregates
containing more than 500 localizations. We manually classified data from the +dox control,
day 1 off dox and day 2 off dox into 4 categories: linear fibrils, branched fibrils, NFT
Precursors, and NFTs. We then used this manual classification to train and test a machine
learning model for predicting different classes of tau aggregates under different conditions
(see more below).
Prior to the prediction of different tau classes using machine learning, we first performed
a simpler principal component analysis (PCA) on the tau aggregates from +dox, day 1, 2,
3, 4, 5 and 10 off dox to look for similarities as well as differences between these
conditions. Principal component analysis (PCA) is a technique that uses a linear
combination of the original variables to create new, uncorrelated, variables (called latent
variables). This data transformation reduces the number of variables while preserving as
much of the information as possible. In this particular example, the original data consists
of a series of spatial shape descriptors that describe the tau aggregates, including
geometric (e.g., area, number of localizations, etc.), boundary (e.g., elasticity, bending
energy, etc.), image-related (e.g., texture, grayscale intensity, etc.), fractal (e.g.,
Minkowski dimension, Haussdorff area, etc.), skeleton (e.g. cloud width, mean length,
etc.), and moments (e.g. inertia, dispersion, etc.) descriptors. Data from the +dox control,
day 1 and day 2 off dox completely overlapped in the PCA space indicating that there are
many similarities in the characteristics (shape, size) of tau aggregates present in these
groups, which is consistent with our observation that substantial degradation does not
56

start until day 3 off dox (Fig. 4.1B, SI Appendix C, Fig. C2A). We further compared the
PCA plots of the manually classified subsets of linear fibrils (SI Appendix C, Fig. C2B),
branched fibrils (SI Appendix C, Fig. C2C), NFT Precursors (SI Appendix C, Fig. C2D),
and NFTs (SI Appendix C, Fig. C2E). While these different classes were separated in the
PCA space as expected (SI Appendix C, Fig. C2F), each individual class showed a high
degree of overlap when comparing the +dox control, day 1 and day 2 off dox, suggesting
that these classes have similar characteristics in +dox, 1 and 2 days off dox conditions.
Since the data between these three experiments were so similar, we represented them as
one color in the PCA plot along with data from day 3, 4, 5 and 10 off dox represented as
different colors (Fig. 4.2A, B, SI Appendix C, Fig. C3). We noticed that the data points
belonging to day 4, 5 and 10 off dox showed a shift towards the upper left quadrant of the
PCA space compared to +dox, 1 and 2 days off dox (Fig. 4.2A, B). When we compared
the data from later days off dox (4, 5 and 10 days) to the manually classified classes of
linear/branched fibrils and NFT Precursors/NFTs, we saw that the observed shift
corresponded to a shift towards linear/branched fibrils and away from NFT
Precursors/NFTs (Fig. 4.2C, D). These results suggest that NFT Precursor and NFT
aggregates have been either already degraded or broken down at these later time points,
whereas the linear/branched fibrils are still remaining.
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Figure 4.2: PCA reveals differences in tau aggregate structures from different days off dox. A, B.
2-D and 3-D PCA plot of tau aggregates from cells from +dox control (grey), Day 1 (grey), Day 2
(grey), Day 5 (red) and Day 10 off dox (blue). C, D. 2-D and 3-D PCA plots of tau aggregates from
cells of Day 4, 5 and 10 off dox (blue) superimposed with tau aggregates from +dox, Day 1 and
Day 2 that are either linear or branched fibrils (grey) or NFT and NFT Precursor structures (red).

To further support these results, we used the machine learning approach to classify tau
aggregates into distinct aggregate classes. We first trained the model on a subset of the
manually classified tau aggregates and then used the model to predict the remaining
subset of manually classified tau aggregates that were not used for the training. To
determine the robustness of the model in classifying tau aggregates, we generated a
confusion matrix to compare the classified classes to the true classes (determined from
the manual classification) (Fig. 4.3A). The probability that a prediction would match the
true class was high for all types of classes, giving high confidence that the classification
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can robustly distinguish different classes of tau aggregates. We then used the machine
learning to predict tau classes present in the entire dataset from +dox control and Days 110 off dox conditions and plotted the percentage of aggregates belonging to each class
on different days. Interestingly, the proportion of linear fibrils increased starting at around
4 days off dox while the proportion of NFT Precursors and NFTs decreased (Fig. 4.3B).
The proportion of branched fibrils stayed steady (Fig. 4.3B). These results suggest that
NFT precursors and NFTs are more efficiently cleared or broken apart while fibrils,
particularly linear fibrils are more resistant to degradation and are less efficiently cleared
over time.
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Figure 4.3: Linear fibrils persist longer than other tau aggregates following dox removal. A.
Confusion matrix showing the confidence of the class predictions in % accompanied by
representative STORM images of each class. B. Stacked bar plots showing the percentage of tau
aggregate structures that belong to each of the four classes in cells from +dox control, Day 1, 2, 3,
4, ,5 and 10 off dox. C. Stacked bar plots showing the percentage of tau aggregate structures that
belong to each of the four classes in cells from Day 1 off dox, Day 1 off dox and CQ and Day 1 off
dox and epo.
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Autophagy and UPS clear distinct classes of tau aggregates

To determine which degradation pathways are responsible for clearance of tau aggregates
following the removal of soluble tau from Clone 4.1 cells, we employed inhibitors of the
autophagy and UPS pathways. More specifically, we used chloroquine diphosphate (CQ),
a widely used autophagy inhibitor, which inhibits the fusion of autophagosomes with
lysosomes by lowering the lysosomal pH (Mauthe et al. 2018). We either added 30 μM
CQ simultaneously while removing Dox and treated for 1 day (day 1 off dox and CQ). In a
second set of experiments, we added 30 μM CQ after cells had been without dox for 1
day and treated for 1 day (day 2 off dox and CQ) (Fig. 4.4A). To ensure that the treatments
indeed inhibited autophagy, we performed a Western blot in cell lysates from Clone 4.1
cells. There was a decrease in autophagy flux indicated by the presence of both LC3-I
and LC3-II in lysate from cells treated with CQ for 1 day together with dox removal (day 1
off dox and CQ) compared to cells from +dox or day 1 off dox control without CQ treatment
(SI Appendix C, Fig. C4A). Similar results were obtained for day 2 off dox and CQ
compared to +dox or day 2 off dox control without CQ treatment (SI Appendix C, Fig.
C4B). Additionally, we transfected Clone 4.0 cells with a plasmid containing LC3, an
autophagosomes marker, fused to mRFP and eGFP. When autophagosomes fuse with
lysosomes to initiate autophagy, lysosomal acidification quenches eGFP but not mRFP.
Therefore, eGFP fluorescence reports autophagosomes before fusion whereas mRFP
fluorescence reports both autophagosomes and autolysosomes (Mohan et al. 2019). We
compared cells in the following conditions: day 2 off dox and day 2 off dox and 30 μM CQ.
On day 2 off dox, there were more autolysosomes present than autophagosomes as is
expected when autophagy is active (SI Appendix C, Fig. C4C). On day 2 off dox and 30
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μM CQ, there were much fewer autolysosomes present consistent with autophagy
inhibition (SI Appendix C, Fig. C4D).

Figure 4.4: Autophagy and UPS inhibition lead to tau aggregate accumulation. A. Schematic of CQ
and epo treatments. B. SMLM images of tau in the FTDP-17 cell model, where dox has been
removed for one or two days and 30uM of autophagy inhibitor, chloroquine diphosphate (CQ) has
been added either on day 1 off dox or day 2 off dox. Scale bar in inset is 1μm. C and D. Plots of
the median fold change in tau protein density in cells exhibiting tau aggregation following removal
of dox for one or two days and/or treatment with autophagy inhibitor, CQ on day 1 or day 2 off dox.
C: +dox control: n= 18 cells, n= 2 experiments, Day 1 off dox: n= 14 cells, n= 2 experiments, Day
1 off dox and CQ: n= 17 cells, n=2 experiments. D: + dox control: n= 10 cells, Day 2 off dox: n= 10
cells, Day 2 off dox and CQ: n= 7 cells. E. SMLM images of tau in the FTDP-17 cell model, where
dox has been removed for one day and/or 20nM of proteasome inhibitor, epoxomicin (epo) has
been added on day 1 off dox for 6hr and replaced with off dox cell media. Scale bar in inset is 1μm.
F. Plots of the median fold change in tau protein density in cells exhibiting tau aggregation following
removal of dox for one day and/or treatment with epo on day 1 off dox. +dox control: n= 13 cells,
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n= 2 experiments, Day 1 off dox: n= 13 cells, n= 2 experiments, Day 1 off dox and epo: n= 15 cells,
n= 2 experiments. Error bars indicate standard deviation (SD).

Addition of CQ led to further accumulation of tau protein in both treatments (Fig. 4.4B). In
the case of day 1 off dox quantitative analysis of the tau localization density in each
condition revealed that CQ treatment led to a 1.5-fold increase in tau protein density
compared to the +dox control and almost a 2-fold increase compared to tau aggregates
from day 1 off dox without CQ treatment (Fig. 4.4C). These results suggest that there is a
basal level of tau degradation in these cells even prior to turning dox off, which, when
inhibited leads to further accumulation of tau. Day 2 off dox with CQ treatment also led to
an accumulation of tau protein compared to day 2 off dox without treatment, but not
compared to +dox, which could mean that there are other compensatory degradation
mechanisms like UPS that are active at this later point or that some degradation has
already happened between +dox and day 1 off dox prior to CQ treatment (Fig. 4.4D). It
should be noted that these latter results are preliminary and further biological replicates
are needed for confirming these conclusions.
To test the involvement of UPS pathway, we employed a commonly used proteasome
inhibitor called epoxomycin (epo), which modifies catalytic subunits of the 20S proteasome
resulting in its inhibition (Meng et al. 1999). To ensure that this treatment led to
proteasome inhibition, we performed a Western blot on lysates from cells in all conditions
and specifically looked at ubiquitination. There was a slightly higher amount of
ubiquitination in the treatment groups compared to the non-treated controls after
normalizing for well loading as expected (SI Appendix C, Fig. C5A, B). Addition of 20nM
of epo while simultaneously removing dox for 1 day (day 1 off dox and epo) also led to an
accumulation of tau protein as with CQ (Fig. 4.4E). Similarly, as with CQ, there was an
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approximate 1.5-fold increase compared to +dox and almost a 2-fold increase compared
to day 1 off dox (Fig. 4.4F).
We next carried out a similar analysis on data from autophagy and proteasome inhibition
experiments. PCA analysis showed that data from the CQ and epo treatment overlapped
with data from day 1 off dox in the PCA space, suggesting that both conditions contain tau
aggregate species having the physical characteristics of the full range of tau aggregate
classes present. Interestingly, there was not a full overlap between data from the CQ and
epo experiments in the PCA space, suggesting that they could possess slightly different
tau aggregate sub-populations (SI Appendix C, Fig. C6A, B).
Finally, we used the machine learning based classification to predict the tau aggregate
classes present upon CQ and epo treatment compared to untreated control conditions.
Interestingly, the proportion of linear fibrils increased by 2-fold compared to other tau
aggregate classes in cells treated with epo compared to day 1 off dox cells (Fig. 4.3C).
On the other hand, the proportion of NFT Precursors and NFT-like structures slightly
increased in cells treated with CQ (Fig. 4.3C). These results suggest that UPS is likely
involved in the degradation of linear fibrils, which accumulate following proteasome
inhibition (Fig. 4.5). Based on the results that linear fibrils also accumulate in 4-10 days
off dox without treatment, it is possible that UPS becomes overwhelmed and can no longer
degrade fibrils at these later time points (Fig. 4.5). Furthermore, our results also suggest
that autophagy is more likely to be involved in the clearance of NFT precursors and NFTs,
since these structures accumulate upon autophagy inhibition (Fig. 4.5). Branched fibrils
could also be a by-product of breakdown of the NFT precursor and NFT tau aggregates
by autophagy, in addition to smaller tau species like oligomers and monomers, which then
associate with the microtubules (Fig. 4.5).
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Figure 4.5. Working model of tau aggregate clearance. Created with BioRender.com. In the
illustrated model, linear tau fibrils are degraded by UPS. However, UPS can become overwhelmed
and fail to degrade the linear tau fibrils resulting in their accumulation. NFT Precursors and NFTs
are degraded by autophagy. By-products of those could be branched tau fibrils in addition to tau
monomers and oligomers.

Discussion
Here, we demonstrated using super-resolution microscopy that tau aggregates become
degraded in the absence of soluble tau in an engineered cell model of tau aggregation.
This finding recapitulates what has already been shown by (J. L. Guo et al. 2016) using
this cell model. Understanding how tau aggregates become degraded in this engineered
cell model could have important implications for the development of selective therapeutic
approaches targeting tau aggregate clearance pathways to reverse neurodegeneration.
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Quantitative analysis of our results showed that following a cease in soluble tau
expression, the number of small tau aggregates (<500 localizations) was reduced first and
then reached a plateau while the number of larger tau aggregates (>500 localizations)
was reduced gradually over time. One interpretation could be that small tau aggregates
get degraded first followed by larger tau aggregates which get degraded gradually over
time. An alternative interpretation could be that large tau aggregates become broken down
into smaller ones at later time points and those smaller aggregates then become
degraded. In either case, it is highly likely that breakdown of large tau aggregates into
smaller units takes place. In some cases, such breakdown of tau aggregates has been
shown to exacerbate neurodegeneration by contributing to the generation of toxic tau
fragments (Y. P. Wang et al. 2007). However, breakdown of tau aggregates also has the
potential to facilitate tau aggregate clearance as chaperone proteins can associate more
easily with tau fragments and facilitate their degradation (Yipeng Wang et al. 2009).
In the cell model we are using, clearance of tau aggregates is successful and by day 10
off dox, most NFT precursor and NFT aggregates have been cleared almost completely
with a return to microtubule associated tau, which resembles more physiological state of
tau localization. This result suggests that large tau aggregates are likely a sink for tau
protein and once these large tau aggregates are cleared, the remaining tau has higher
affinity for microtubules. The process of tau aggregate clearance is often full of roadblocks
in tauopathies. Findings from this cell model likely do not fully recapitulate the complexity
of the human brain, but elucidating how degradation occurs in this simpler system could
offer direction regarding the main targets to focus on in the brain. Particularly, our findings
using machine learning based shape classification of tau aggregates showed that linear
tau fibrils increase in proportion over time, suggesting that these aggregates may be
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harder to degrade. Understanding the reasons behind why this aggregate species is more
resistant to degradation can potentially offer avenues for facilitating their clearance.
Previously, we showed that these linear fibrils are enriched in hyperphosphorylation marks
in Ser 202/Thr205 (Gyparaki et al. 2021). One potential explanation could be that
hyperphosphorylation at these residues is refractive to tau degradation, a hypothesis that
can be explored in future work.
We next examined the involvement of the two main degradation pathways: UPS and
autophagy in the clearance of tau aggregates in Clone 4.1 cells. We showed that
pharmacological inhibition of UPS or autophagy leads to an accumulation of tau
aggregates. Interestingly, we found that autophagy inhibition led to an increase in NFT
Precursors and NFTs. These results agree with the already existing literature where
autophagy has been shown to degrade both soluble and insoluble forms of tau as well as
both wild-type and mutant forms of tau (Dolan and Johnson 2010) (Y. Wang et al. 2010).
UPS inhibition led to a greater increase in the number of linear fibrils than autophagy
inhibition, which suggests that UPS could be involved in the clearing of those aggregate
species to a greater extent than autophagy. An increase in tau accumulation following
UPS inhibition is consistent with the literature (David et al. 2002) (Liu et al. 2009) (J. Y.
Zhang et al. 2005). However, due to size limitations of the proteolytic core of the
proteasome, tau aggregates are not thought to be degraded by UPS. Our findings indicate
that the proteasome is possibly involved in more than the degradation of tau monomers
and small oligomers as it was previously thought (Rubinsztein 2006). Based on our
findings, we propose a model, where tau fibrils are targeted by UPS for degradation but
UPS becomes overwhelmed and cannot properly degrade those structures leading to their
accumulation. Moreover, we propose that NFT Precursors and NFTs are degraded by
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autophagy and broken down into tau monomers and oligomers as well as tau branched
fibrils. The branched fibrils remained similar in proportion throughout the different days
following dox removal. This could be due to branched fibrils being a byproduct of
degradation of larger structures and incomplete clearance of branched fibrils by
autophagy. In fact, a similar behavior has been observed with α-synuclein, which is
another aggregation-prone protein (Grassi et al. 2018). Trimming of α-synuclein into a
smaller and more toxic aggregate structure is a result of a failed autophagic process. As
a next step, it would be important to determine whether this model holds true in neurons,
which could further inform therapeutic strategies targeting cellular degradation
mechanisms.
Materials and Methods
A detailed description of the methods can be found in SI Appendix C. Briefly, a stable
human embryonic kidney-derived QBI-293 cell lines (Clone 4.1) expressing full-length
human tau T40 (2N4R or 4R) carrying the P301L mutation with a GFP tag, a kind gift from
the V. Lee laboratory at the University of Pennsylvania, Philadelphia, PA, was used for
experiments. Clone 4.1 is sorted from the parent Clone 4.0 cell line to enrich for large,
compact tau aggregates after exogenous tau fibril addition. Clone 4.1 was maintained in
Dox continuously (+dox) or Dox was removed from the culture media for several days to
perform experiments (Day 1 off dox, Day 2 off dox etc). Pharmacological treatments of
Clone 4.1 cells were performed by incubating the cells with media containing either 20nM
epo or 30μM CQ. Cells were grown on chambered coverglass, fixed with ice cold
methanol, and immunostained with GFP nanobody fused to AlexaFluor 647 prior to superresolution microscopy using a Nanoimager from Oxford Nanoimaging.
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS

In this dissertation, I have discussed my research findings on the nanoscale distribution
of tau on microtubules and in tau aggregates as well as the characterization of different
tau aggregate species in cell models of disease and how they are degraded by UPS and
autophagy. In chapter 2, I showed that tau forms oligomeric complexes on microtubules
that are different from those present in pathological conditions. Moreover, I found evidence
supporting that microtubule-associated tau dimers/trimers grow in size in pathological
conditions suggesting that aggregation could precede the dissociation of tau from the
microtubules. In chapter 3, I showed that different tau aggregate species could be
distinguished by the phosphorylation markers they possess reinforcing the idea of the
existence of different tau strains. Finally, in chapter 4, I showed that in an engineered
model of tauopathy, removal of soluble tau leads to clearance of tau protein as well as tau
aggregates by degradation regulated by UPS and autophagy. The combination of superresolution imaging and computational approaches I used allowed me to elucidate areas
of limited understanding in the field of tauopathies. In the following sections, I have
summarized some useful future directions and areas to explore based on the improved
understanding we have from our findings.
Microtubule-associated tau oligomers in disease
The canonical disease-state theory for tauopathies posits that tau becomes mutated
and/or hyperphosphorylated, dissociates from the microtubules and then aggregates. Our
findings of microtubule-associated tau dimers/trimers in an engineered cell model of
tauopathy as well as in neurons have recently challenged this traditional view. The idea
that tau aggregation could be seeded on the microtubule by these dimers/trimers prior to
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its dissociation significantly changes how we think of its mechanism of aggregation. More
recently, (Cario et al. 2022) showed that the R5L mutation in the N-terminal domain of tau
disrupted the formation of microtubule-associated tau patches (analogous to what we refer
to as oligomers) but did not affect tau’s microtubule affinity using an in vitro TIRF binding
assay with taxol-stabilized microtubules. It would be interesting to explore this finding in
neurons to study the effect of the R5L mutation and generally tau’s N-terminal projection
domain on the microtubule-associated tau oligomers and tau aggregation. Moreover,
previously, single-molecule tracking revealed that tau dwells on a single microtubule for a
very short time (∼40 ms) in what has been described as a kiss-and-hop interaction before
hoping on to the next microtubule (Janning et al. 2014). These experiments were
performed using a Halo-tagged tau fusion construct. Since microtubule-associated tau
consists of tau oligomers in addition to monomers, a crucial future direction would be to
explore whether this dynamic interaction of tau with the microtubules changes when tau
exists in larger complexes. Additionally, it is worth exploring whether there is a cut-off
number of the molecules in a tau oligomeric complex after which the complex cannot reassociate with the microtubules dynamically and therefore, falls off and continues to
aggregate in the cytosol. Future findings in this direction would be critical for determining
future therapeutic targets for tauopathies.
Distinguishing tau aggregates based on their post-translational modifications
Our work showed that it is possible to distinguish different tau aggregate species based
on their shape and other characteristics such as their phosphorylation markers. One of
the most unanswered questions despite the extensive research in the field is what exactly
drives tau aggregation and whether it holds true for all types of tau aggregates. Based on
what we know so far, different tauopathies have neurodegeneration in common but in
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most cases, their clinical presentation differs and the tau aggregates present in each
consist of different tau isoforms. To start, it is helpful to identify certain characteristics that
drive aggregation and could be present in most tau aggregates. For instance, the Ser
202/Thr 205 phosphorylation site of tau combined with phosphorylation at Ser 208 and
absence of phosphorylation at Ser262 has been shown to readily form fibers of tau in vitro
without the addition of any aggregation inducer (Despres et al. 2017). However, it is not
clear whether these phosphorylation markers are also present in smaller tau aggregates
such as oligomers. Therefore, it would be crucial to characterize different stages of tau
aggregate species and determine common phosphorylation markers as well as other posttranslational modifications (PTMs) that perhaps are acquired in early stages and persist
as well as others that are added along the way.
Most phosphorylation markers of tau are present on the C-terminal half of the protein
(Flores-Rodríguez et al. 2015). Biochemical analysis of sarkosyl-insoluble tau from
patients of different tauopathies shows distinct patterns of C-terminal tau fragments (Arai
et al. 2004) (Taniguchi-Watanabe et al. 2016). Moreover, tau filaments extracted from
patients of different tauopathies also exhibit ultrastructural differences at the atomic level
as revealed by cryo-EM studies (Sanders et al. 2014) (Kaufman et al. 2016) (Arakhamia
et al. 2020). More recently, such differences have been attributed to PTMs of tau and not
limited to hyperphosphorylation (Arakhamia et al. 2020). Ubiquitination of tau residues and
specifically, the C terminus of ubiquitin stabilizes the interprotofilament surface in filaments
of tau from AD. (Arakhamia et al. 2020) proposed a model where the incorporation of
ubiquitin into the tau protofilaments from AD and CBD could facilitate the interprotofilament packing process and lead to ultrastructurally distinct polymorphs. The
unsupervised machine learning approach we developed could offer insight into the
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distinction of different tau aggregate species based on their shape and PTMs and could
complement parallel work using cryo-EM and mass spectroscopy (MS) - based
proteomics.
Exploiting autophagy and UPS to target different tau aggregate species
Determining how distinct tau aggregate species get degraded by autophagy or UPS could
revolutionize therapies for tauopathies. To tackle this puzzle, we employed
pharmacological treatments that inhibit UPS or autophagy and studied the tau aggregate
populations which accumulate thereafter. In the future, we hope to expand our current
approach to also implement supervised machine learning in combination with modeling.
The goal is to create models for each type of tau aggregate present in a sample and
examine whether the same tau aggregate populations are present under various treatment
conditions. This approach could tell us if specific tau aggregates are resistant to
degradation as well as which specific tau aggregates are more efficiently cleared by UPS
or autophagy. This approach would not only be useful for segmented tau aggregates from
super-resolution images but could also be used in combination with different types of light
as well as electron microscopy samples. For instance, analyzing tau aggregates from
post-mortem tauopathy brain tissue, which contain a specific set of PTM markers and
comparing those from different tauopathies could facilitate the detection of distinct tau
strains.
An important PTM, which also regulates degradation is ubiquitination. Ubiquitin most
commonly, marks proteins for degradation by the proteasome and it contains seven lysine
(K) chains (Swatek and Komander 2016). How these residues become ubiquitinated can
determine the fate of a protein. K48-linkage has been implicated in proteasomal
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degradation, whereas K63-linkage has been implicated in autophagy (Swatek and
Komander 2016) (J. M. M. Tan et al. 2008). However, recently, K63-linked ubiquitination
of AD brain derived tau oligomers was shown to contribute to AD pathogenesis
(Puangmalai et al. 2022). Therefore, examining the type of ubiquitin linkage in distinct tau
aggregates from different tauopathies would also contribute to our understanding of tau
strains but also which tau aggregate species are potentially targeted for degradation by
the proteasome and/or autophagy.
Furthermore, understanding how autophagy and UPS malfunction in tauopathies, whether
their malfunction is caused solely by the presence of an overwhelming amount of tau
aggregates and whether it is influenced by additional factors is essential. In the future,
monitoring the efficiency of autophagy and the UPS with inducible systems of tau
aggregation similar to the cell model we used could elucidate whether failure to clear
aggregates could be due to increasing tau aggregate concentration or due to the presence
of specific tau aggregate species. Previously, age-dependent increases in phosphorylated
tau have led to defective autophagy in AD (Reddy and Oliver 2019). Moreover, other
studies have shown that accumulation of tau aggregates inhibits the fusion of the
autophagosome with the lysosome in AD (Feng et al. 2020). Interestingly, proteasomal
activity but not tau protein level has been shown to decrease in AD affected brain regions
compared to unaffected (Keller, Hanni, and Markesbery 2000). An interesting direction
would be to explore whether tau oligomers specifically impair the function of the
proteasome, as previously other protein oligomers seen in neurodegenerative diseases
have been implicated in an oligomer-driven impairment of the 20S proteasome that might
also hold true for tau (Thibaudeau, Anderson, and Smith 2018).
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Tau aggregates and membrane interactions
In recent years, we have gained a better understanding into how tau aggregates are
transported from one neuron to the next. In fact, both tau monomers and pathological tau
aggregates can be released from a donor cell and taken up by a recipient cell (De LaRocque et al. 2021). Moreover, there is evidence that tau secretion can occur in a vesicledependent way through exosomes or ectosomes but also via more unconventional, nonvesicular pathways involving translocation across the plasma membrane (G. Lee and
Leugers 2012) (Dujardin et al. 2014) (Katsinelos et al. 2018) (Merezhko et al. 2018).
Therefore, understanding how different tau aggregates species are interacting with the
plasma membrane and transported to recipient cells would have important implications for
the spread of neurodegenerative diseases. Our super-resolution images can be acquired
using the Total Internal Reflection Fluorescence Microscopy (TIRFM) modality, which is
ideal for studying the membrane since it can illuminate fluorophores near the membrane
through the generation of an evanescent field (Fish 2009). An important future direction
would be to image tau along with components of the plasma membrane and examine the
distribution of the protein across the plasma membrane in physiological and pathological
conditions. In particular, it would be important to explore how tau PTMs and specifically
phosphorylation affect its interaction with the membrane. The existing data is conflicting
so far because studies have used different cell lines containing different tau species and
studied different phosphorylation sites, making it challenging to reach a consensus (Bok
et al. 2021). It is speculated that phosphorylation of physiological tau has an inhibitory
effect on its association with the membrane whereas phosphorylation of tau oligomers and
fibrils has the opposite effect (Bok et al. 2021). However, these findings need to be
carefully validated.
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Furthermore, once tau dissociates from the microtubules, it is likely that it interacts with
other membranous organelles such as the endoplasmic reticulum (ER) and mitochondria.
Increased tau has been observed on the surface of the rough ER in the brains of AD
patients (Perreault et al. 2009). Additionally, increased mitochondria-ER contacts have
also been reported in the brains of those patients, which could be related to the increased
tau also observed (Perreault et al. 2009). Elucidating the involvement of tau in the
regulation of mitochondria-ER contacts would shed light on other ways it could be
contributing to neurodegeneration by altering mitochondrial dynamics, apoptosis, lipid
metabolism among other processes (Csordás, Weaver, and Hajnóczky 2018) (Moltedo,
Remondelli, and Amodio 2019).

75

APPENDICES
APPENDIX A.

Supplementary Materials and Methods for Chapter 2
Cell culture

A stable cell line expressing 3R-WT-GFP tau was derived from African green monkey
(Cercopithecus aethiops) kidney epithelial cells (BSC-1; CCL-26; American Type Culture
Collection). For some experiments, BSC-1 cells were transfected with either a 4R-WTGFP tau construct or a 4R-WT tau construct to transiently express tau (see Figures S1A,
S2B, S3G,H). Cells were grown in complete growth medium (Eagle’s minimum essential
medium with Earle’s salts and non-essential amino acids plus 10% FBS, 1mM sodium
pyriuvate, 2mM L-glutamine, 500 ug/ml Geneticin [G418 Sulfate; Thermo Fisher Scientific]
and penicillin-streptomycin) in a 37°C incubator containing 5% CO2.

Two stable human embryonic kidney-derived QBI-293 cell lines (Clone 4.0, Clone 4.1)
expressing full length human tau T40 (2N4R) carrying the P301L mutation with a GFP tag,
a kind gift from the V. Lee lab at the University of Pennsylvania, were used for the majority
of experiments. Clone 4.1 was originally sorted from the parent Clone 4.0 cells to enrich
for large compact tau aggregates after exogenous tau fibril addition (J. L. Guo et al. 2016).
Cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
tetracycline-screened fetal bovine serum (FBS), 1% pyruvate (10mM), 1% penicillinstreptomycin and L-glutamine (20 mM), 5ug/ml blasticidin, 200ug/ml Zeozin and were
maintained in a 37°C incubator containing 5% CO2. Clone 4.1 was maintained in media
containing 100ng/mL of Doxycycline (Dox), whereas 100ng/nL of Dox was only added in
the media overnight (16-24 h) before fixation for Clone 4.0 unless otherwise stated in order
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to express the 4R-P301L-GFP tau construct. For all imaging, cells were plated on eightwell Lab-Tek 1 coverglass chambers (Nunc).

E18 Sprague-Dawley rat hippocampal neurons were obtained in suspension from the
Neuron Culture Service Center at the University of Pennsylvania. Neurons were plated in
eight-well Lab-Tek 1 coverglass chambers (Nunc) which had been precoated with 0.5
mg/ml poly-L-lysine (Sigma-Aldrich) 24 hr before plating. Neurons were cultured in
maintenance media consisting of Neurobasal (Gibco) supplemented with 2mM GlutaMAX,
100 U/ml penicillin, 100 mg/ml streptomycin, and 2% B27 (Thermo Fisher Scientific) in a
37°C incubator containing 5% CO2.

Cell lysate extraction and Western blotting

Cell lysate was extracted from QBI cells with Dox-regulated expression of 4R-P301L-GFP
tau (Clone 4.0 grown in the presence (+) or absence (-) of Dox and Clone 4.1 grown in
Dox) by RIPA (Radioimmunoprecipitation) buffer containing phosphatase and protease
inhibitors and incubated on ice for 15 min. Lysates were then centrifuged at maximum
speed on a tabletop centrifuge for 30 min at 4 °C. Protein concentration was determined
using the Bradford assay. 2-3ug of protein per sample were resolved in 4-12% Bis-Tris
NuPAGE (polyacrylamide) gels, transferred to nitrocellulose membranes, and blocked in
Odyssey blocking buffer (Li-Cor Biosciences) before probing with Tau-5 antibody (see
Table S.2.1). The blots were further incubated with IRDye labeled secondary antibodies
and scanned using ODY-2816 Imager (Li-Cor Biosciences). GAPDH was used as a
loading control. Image analysis was performed using Image Studio Lite software (LI-COR).
Fluorescent band intensity was normalized to the GAPDH loading control.
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Immunostaining

Two different fixation protocols were tested: paraformaldehyde (PFA) or methanol fixation.
For PFA fixation, cells were initially washed with PBS for three times (5 min per wash),
then fixed with 4% PFA for 10 min at room temperature and washed again three times (5
min per wash) with PBS following fixation. Since PFA fixation disrupted tau localization,
for the experiments reported in the manuscript, cells were fixed using methanol fixation.
Briefly, cells were first incubated with microtubule stabilizing buffer (MTSB: 15g PIPES,
1.9g EGTA, 1.32 MgSO4·7H2O, 5g KOH, H2O to a liter, pH=7) for 3 min and then ice cold
methanol was added in the buffer for 3 min. Following this short incubation, cells were
washed with MTSB twice. Cells were then blocked for 1hr using 4% (wt/vol) BSA in PBS.
They were then incubated with the appropriate dilution of primary and secondary
antibodies (or nanobody) in blocking buffer consisting of 3% (wt/vol) BSA and 0.2% Triton
X-100 (vol/vol; Thermo Fisher Scientific) in PBS. Cells were washed with washing buffer
(0.2%

BSA

and

0.05%

Triton

X-100;

Thermo

Fisher

Scientific)

between

antibody/nanobody incubations. A list of antibodies/nanobodies used in this study is
provided in Table S.2.1. The nanobody we used was GFP VHH, recombinant binding
protein (gt-250, Chromotek). The secondary antibodies we used were AffiniPure goat antimouse IgG (H+L, 115-005-003; Jackson ImmunoResearch) at a dilution of 1:100, and
AffiniPure donkey anti-rabbit IgG (H+L, 711-005-152; Jackson ImmunoResearch) at a
dilution of 1:100. The nanobody and the secondary antibodies used in this study were
custom-labeled with an Alexa Fluor A647 or Alexa Fluor 405-Alexa Fluor 488 and an Alexa
Fluor 405-Alexa Fluor A647 or Alexa Fluor 405-Alexa Fluor 488 activator/reporter dye pair
combination at 0.12-0.15 mg/ml concentration, respectively (Bates et al. 2007).
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SMLM imaging

SMLM was acquired using an Oxford Nanoimaging system. To avoid bias, images were
randomly acquired and all acquired images were included in the analysis unless there was
substantial drift present in the images, which could not be corrected by post-processing.
The Nanoimager-S microscope had the following configuration: 405-, 488-, 561- and 640nm lasers, 498-551- and 576-620-nm band-pass filters in channel 1, and 666-705-nm
band-pass filters in channel 2, 100 x 1.4 NA oil immersion objective (Olympus), and a
Hamamatsu Flash 4 V3 sCMOS camera. Localization microscopy images were acquired
with 15 ms exposure for 50,000 frames. For multi-color SMLM, 110,000 frames with 15
ms exposure were acquired with sequential laser activation. The images were then
processed using the NimOS localization software (Oxford Nanoimaging).

Data analysis

Voronoi Tesselation Analysis

Localizations were exported in .csv format using the NimOS localization software and
converted to .bin files using MATLAB R2017a. The rendered SMLM images were cropped
using the AFIB plugin in ImageJ (National Institutes of Health) (Schindelin et al. 2012).
Voronoi Tesselation Analysis was performed in MATLAB R2017a similarly to (Otterstrom
et al. 2019) (Levet et al. 2015) (Andronov et al. 2016). First, a Voronoi threshold was
chosen manually to define a Voronoi cluster as a collection of Voronoi polygons with areas
smaller than the given threshold. We confirmed that the selected threshold led to proper
segmentation of the super-resolution images visually and used the same threshold across
different conditions for consistency. In the case of Clone 4.0, we cropped regions in which
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single microtubules were visible and avoided dense areas consisting of microtubule
bundles to avoid segmentation errors due to inability to resolve the tau associated with
individual microtubules within these bundles. The x and y coordinates from the
localizations were processed by the “delaunayTriangulation” function and then the
‘Voronoidiagram” function to generate Voronoi polygons. The Voronoi polygon areas were
calculated from the shoelace algorithm. A new molecule list assigning localizations to
different channels (0-9) according to their Voronoi area was then generated. Next, these
localizations were put into different clusters and their cluster statistics were generated and
used for analysis. The different clusters were pseudocolored based on their channel (0-9)
and visualized using a custom-written software, Insight3 (provided by B. Huang, University
of California, San Francisco, San Francisco, CA; (Huang et al. 2008).

Outlier Removal Analysis

In the segmented clusters, there is a positive correlation between the cluster area and the
number of localizations per cluster. However, clusters corresponding to imaging artefacts
(e.g. molecules that do not photoswitch) fall outside of this positive correlation as they
contain a large number of localizations but small area. We used this positive correlation
between cluster area and the number of localizations to filter clusters corresponding to
imaging artefacts. This procedure removed 0.1316% of clusters from the data.

GFP nanobody Calibration

We determined the number of localizations corresponding to a single tau molecule labeled
with the GFP-nanobody by carrying out super-resolution imaging under dilute labeling
conditions corresponding to a 1:10000 dilution of the GFP-nanobody. We segmented
80

these images using Voronoi segmentation as described above and determined the
number of localizations per cluster. The number of localizations distribution was fit to a log
normal function to extract two parameters mu and sigma corresponding to the log normal
distribution function (f1). The above-mentioned distribution function (f1) and its convolution
with itself two times (f2 = f1*f1) and three times (f3 = f2*f1) is used to determine the
percentage of single-tau molecules, monomers and oligomers by fitting a linear
combination of these functions to the distribution of the number of localizations per cluster
from the actual experiment corresponding to 1:100 dilution of the GFP-nanobody as
previously described (Cella Zanacchi et al. 2017).

SMLM Colocalization Analysis

Colocalization analysis was performed using a custom-built algorithm in MATLAB R2017a
for all multi-color SMLM data. Regions with similar tau density were cropped for
quantitative analysis, avoiding overcrowded regions to minimize segmentation errors. The
threshold on Voronoi polygon size was kept consistent between different conditions and
clusters having fewer than 5 localizations were filtered. First, a list of reference boundaries
from the reference cluster (channel 1) is obtained. The boundaries are then extended by
a set radius (30 nm) and the points inside the boundary are obtained. Next, the points
from the non-reference cluster (channel 2) that fall into the reference cluster are
determined. The percentage of colocalized points in the non-reference clusters is also
determined. A threshold of 40% colocalization is required for a cluster to be considered
colocalized and anything below 40% is considered isolated. This threshold was
determined after qualitative examination of the colocalized clusters visually and used
throughout the analysis for consistency.
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Distance Distribution Correction (DDC) Analysis

The DDC algorithm developed by (Bohrer et al. 2019) was used to correct for blinking in
SMLM images acquired using the GFP nanobody fused to Alexa Fluor A647 or Alexa Fluor
405-Alexa Fluor 488 without 405nm activation as previously explained.

Statistical Analysis

Non-parametric Mann-Whitney tests were performed using OriginPro 2017 software for
all data imaging data sets. A paired student t-test was performed for the fixation control
experiment in Fig. A3B.
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Supplementary Figures for Chapter 2

Fig. A1: Tau localization and microtubule network density in the engineered cell lines. A.
Wide-field images of GFP fluorescence in live BSC-1 cells expressing 3R-WT-GFP tau,
live Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau
expression, fixed BSC-1 cells expressing 4R-WT-GFP tau stained by GFP nanobody
conjugated to AlexaFluor 647, fixed BSC-1 cells expressing 4R-WT tau stained by Tau-5
antibody, which was labeled with a secondary mouse antibody conjugated to AlexaFluor
647. B. Western Blot showing tau and GAPDH (loading control) from lysates of Clone 4.0
cells cultured in the absence of Dox (4.0 –Dox), Clone 4.0 cells expressing 4R-P301LGFP tau after overnight Dox induction (4.0 +Dox) and Clone 4.1 cells maintained in Dox
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and expressing 4R-P301L-GFP tau (4.1). C. Super-resolution image and zoom of αtubulin in Clone 4.0 cells in the absence of Dox induction (i.e no GFP-tau expression) (top
panel). Super-resolution image and zoom of α-tubulin in Clone 4.0 cells expressing 4RP301L-GFP tau after overnight Dox induction of tau expression (non-aggregated tau
expression) (middle panel). Super-resolution image and zoom of α-tubulin in Clone 4.1
cells maintained in Dox and expressing 4R-P301L-tau (aggregated tau expression)
(bottom panel). D. Violin plots showing the total tubulin localization density per nm2
measured by calculating the total number of detected localizations in the super-resolution
images per unit area of the cell. Total localization density was measured in Clone 4.0 cells
cultured without Dox induction of tau expression (-Dox, light green), Clone 4.0 cells after
overnight Dox induction of 4R-P301L-GFP tau expression (+Dox, dark green) and in Clone
4.1 cells maintained in Dox and expressing 4R-P301L-GFP tau (pink). Tubulin localization
density is proportional to microtubule network density. The dashed lines indicate the
median and the dotted lines indicate the 25th and 75th percentile (Clone 4.0 -Dox: n=12
cells, n=2 experiments, Clone 4.0 +Dox: n=10 cells, n=2 experiments, Clone 4.1: n=9 cells,
n=2 experiments). ****, p<0.0001.
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Fig. A2: Representative images of tau in different cell lines used in this study. A. Superresolution images of tau in Clone 4.0 expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression, stained with a GFP nanobody conjugated to AlexaFluor 647.
B. Super-resolution images of tau in BSC-1 cells expressing 4R-WT-GFP tau, stained with
GFP nanobody conjugated to AlexaFluor 647. C. Super-resolution images of oligomeric
tau detected by the tau oligomer specific T22 antibody in Clone 4.0 expressing 4R-P301LGFP tau after overnight induction of tau expression. D. Super-resolution images of tau in
rat hippocampal neurons, stained with Tau-5 antibody, which detects all tau isoforms. E.
Super-resolution images of oligomeric tau detected by tau oligomer specific T22 antibody
in rat hippocampal neurons.
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Fig. A3: Tau forms nano-clusters on microtubules.
A. Wide-field images of GFP fluorescence in Clone 4.0 cells expressing 4R-P301L-GFP
tau after overnight Dox induction of tau expression, fixed with either PFA or MeOH. B. Bar
plots showing the mean fluorescence intensity of GFP-tau in AU before (pre-) and (post-)
methanol fixation in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression (n=5 cells). **, p<0.01. C. Super-resolution image of α-tubulin
staining in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of
tau expression, and zoom. D. Voronoi segmentation of a region of a Clone 4.0 cell
expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression and zoom.
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The different colors represent different nano-clusters whose center is represented by a
white dot. Individual fluorophore localizations are represented as color-coded crosses.
Localizations that are in close spatial proximity are segmented as belonging to the same
nano-cluster. E. Violin plots showing the area of Voronoi segmented nano-clusters in nm2
in the different cell lines used in this study (green: Clone 4.0 cells expressing 4R-P301LGFP tau after overnight Dox induction of tau expression; yellow: stable BSC-1 cells
constitutively expressing 3R-WT-GFP tau; and cyan: rat hippocampal neurons). Plots for
Fig. 1A, Fig. 1B correspond to the quantification of tau nano-clusters stained and imaged
with a GFP-nanobody. Plot for Fig. 1H corresponds to the quantification of tau nanoclusters stained and imaged with a Tau-5 antibody. Plots for Fig. 1C and 1I correspond to
the quantification of tau nano-clusters stained and imaged with the oligomeric T22
antibody. The dashed lines indicate the median and the dotted lines indicate the 25th and
75th percentile (Fig.1A: n=15 cells, n= 3 experiments, Fig.1B: n=15 cells, n=2 experiments,
Fig.1C: n=19 cells, n=3 experiments, Fig.1H n=3 cells, Fig.1I: n=3 cells). F. Violin plots
showing the mean fluorescence intensity (AU) in conventional fluorescence images of tau
in live BSC-1 cells expressing 3R-WT-GFP tau as well as in live Clone 4.0 cells expressing
4R-P301L-GFP tau after overnight Dox induction of tau expression. The fluorescence
intensity of GFP-tau is proportional to the tau expression level in the two cell lines. The
dashed lines indicate the median and the dotted lines indicate the 25th and 75th percentile
(3R-WT-GFP tau: n=20 cells, Clone 4.0: n=20 cells). ****, p<0.0001. G. Violin plots
showing the mean fluorescence intensity (AU) in conventional fluorescence images of tau
in live BSC-1 cells, transiently transfected with 4R-WT-GFP tau, that either express low
(yellow with lines) or high (yellow without lines) levels of GFP-tau. The dashed lines
indicate the median and the dotted lines indicate the 25th and 75th percentile (low: n= 6
cells, high: n= 4 cells). ****, p<0.0001. H. Violin plots showing the number of localizations
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per nano-cluster in super-resolution images of tau in BSC-1 cells, transiently transfected
with 4R-WT-GFP tau, that either express low (yellow with lines) or high (yellow without
lines) levels of GFP-tau. The dashed lines indicate the median and the dotted lines
indicate the 25th and 75th percentile (low: n= 6 cells, high: n= 4 cells). ****, p<0.0001. I.
Violin plots showing the number of localizations per nano-cluster in super-resolution
images of tau in Clone 4.0 cells expressing 4R-P301L-GFP tau that have been induced
with Dox for either 1 day or 2 days. The dashed lines indicate the median and the dotted
lines indicate the 25th and 75th percentile (day 1: n= 6 cells, day 2: n= 7 cells). ns, nonsignificant.
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Fig. A4: Tau nano-clusters consist of monomers, dimers and trimers. A. Super-resolution
images of GFP-tau in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression and before/after DDC correction. Color map corresponds to
localization density with less dense regions shown in blue and denser regions shown in
red. B. Violin plots showing the number of localizations per Voronoi segmented nanocluster in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of
tau expression and before/after DDC correction. The dashed lines indicate the median
and the dotted lines indicate the 25th and 75th percentile (n=15 cells, n=3 experiments).
****, p<0.0001. C. Violin plots showing the area of Voronoi segmented nano-clusters in
nm2 in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau
expression and before/after DDC correction. The dashed lines indicate the median and
the dotted lines indicate the 25th and 75th percentile (n=15 cells, n=3 experiments). ****,
p<0.0001. D. Super-resolution image of tau stained with GFP nanobody conjugated to
AlexaFluor 647 in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression, where the GFP nanobody has been diluted 100-fold more
than in the usual imaging conditions and zoom. Color map corresponds to localization
density with less dense regions shown in blue and denser regions shown in red. E. Box
plots showing the number of localizations per Voronoi segmented nano-cluster in normal
labeling conditions corresponding to 1:100 dilution of the GFP nanobody and in dilute
labeling conditions corresponding to 1:10,000 dilution of the nanobody. (1:100: n=15 cells,
n=3 experiments, 1:10,000: n=5 cells) in Clone 4.0 cells expressing 4R-P301L-GFP tau
after overnight Dox induction of tau expression. Box corresponds to 25-75 percentile, line
corresponds to median and whiskers correspond to the minimum and maximum. A zoom
of the box plot is shown as inset. ****, p<0.0001. F. Super-resolution images of tau in
Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau
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expression, where the GFP nanobody has been diluted 100-fold more (1:10,000) than in
the usual imaging conditions, before and after DDC correction. Color map corresponds to
localization density with less dense regions shown in blue and denser regions shown in
red. Yellow circles indicate GFP tau nano-clusters before and after DDC correction. G.
Plot showing the number of localizations per nano-cluster under dilute labeling conditions
(red) and the log normal fit (blue) used as calibration function (f 1) for monomeric tau in
Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau
expression and stained with GFP nanobody conjugated to AlexaFluor 647. H. Plot
showing the number of localizations per nano-cluster under normal (experimental) labeling
conditions (red) in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox
induction of tau expression, dimeric and trimeric calibration functions (f 2 and f3) (green)
obtained by linear convolution of the monomeric calibration function (f1) obtained from the
log normal fit in (G), and the fit of the experimental data to a combination of f 1, f2 and f3
(blue) with weights w1, w2 and w3 corresponding to the proportion of monomers, dimers
and trimers. I. Plot showing the number of localizations per nano-cluster under normal
(experimental) labeling conditions (red) in BSC-1 cells expressing 3R-WT-GFP tau,
dimeric and trimeric calibration functions (f2 and f3) (green) obtained by linear convolution
of the monomeric calibration function (f 1) obtained from the log normal fit in (G), and the
fit of the experimental data to a combination of f1, f2 and f3 (blue) with weights w1, w2 and
w3 corresponding to the proportion of monomers, dimers and trimers. J. Box plots showing
the number of localizations per Voronoi segmented nano-cluster in normal labeling
conditions corresponding to 1:100 dilution of the Tau-5 primary antibody and the
secondary anti-mouse antibody labeled with AlexaFluor 647 and in dilute labeling
conditions corresponding to 1:10,000 dilution of the Tau-5 primary antibody and 1:100
dilution of the anti-mouse secondary antibody labeled with AlexaFluor 647 in rat
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hippocampal neurons. (1:100: n=7 cells, n=2 experiments, 1:10,000: n=6 cells, n=2
experiments). Box corresponds to 25-75 percentile, line corresponds to median and
whiskers correspond to the minimum and maximum. A zoom of the box plot is shown as
inset. ****, p<0.0001.

Fig. A5: Tau oligomers in Clone 4.1 cells contain more tau protein than the tau oligomers
in Clone 4.0 cells. A. Two-color super-resolution images of tau stained with GFP nanobody
conjugated to AlexaFluor 647 (magenta), or AlexaFluor 488 (cyan) and zoomed in overlay
of two different regions (yellow boxes) in Clone 4.1 cells maintained in Dox and expressing
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4R-P301L-GFP tau. The results of the co-localization analysis are shown in which tau
structures imaged with AlexaFluor488 that co-localize with tau structures imaged with
AlexaFluor647 are shown in magenta and isolated tau structures imaged with
AlexaFluor488 that did not co-localize with tau structures imaged with AlexaFluor647 are
shown in yellow. B. Violin plots showing the area of Voronoi segmented nano-clusters in
nm2 in Clone 4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau
expression (green) and Voronoi segmented tau objects in Clone 4.1 maintained in Dox
and expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression (pink).
The dashed lines indicate the median and the dotted lines indicate the 25th and 75th
percentile (Clone 4.0: n=15 cells, n=3 experiments, Clone 4.1: n=20 cells, n=3
experiments). ****, p<0.0001. C. Plot showing the number of localizations per tau object
under normal (experimental) labeling conditions (red) in Clone 4.1 cells maintained in Dox
and expressing 4R-P301L-GFP tau, dimeric-heptameric calibration functions (f2-f7)
(green) obtained by linear convolution of the monomeric calibration function (f 1) obtained
from the log normal fit in (Fig. A4G), and the fit of the experimental data to a combination
of f1-f7 (blue) with weights w1-w7 corresponding to the proportion of monomers, dimers,
trimers and higher order oligomers.
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Fig. A6: Representative images of tau in Clone 4.1 cells maintained in Dox and expressing
4R-P301L-GFP tau in an aggregated state. Super-resolution images of tau in Clone 4.1
cells maintained in Dox and expressing 4R-P301L-GFP tau, stained with GFP nanobody
conjugated to AlexaFluor 647.
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Antibody

Host species

Catalog number

Vendor

α-tubulin

Rabbit

ab18251

Abcam

T22

Rabbit

ABN454

Sigma-Aldrich

Thr231

Mouse

MN1040

ThermoFisher
Scientific

AT8

Mouse

MN1020

ThermoFisher
Scientific

GFP Binding
Protein

Alpaca

gt-250

ChromoTek

Tau-5

Mouse

AHB0042

ThermoFisher
Scientific

GAPDH

Mouse

A01622-40

GenScript

Table S.2.1. Antibodies used in this study
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APPENDIX B.

Supplementary Materials and Methods for Chapter 3
Data analysis

Iterative Hierarchical Clustering (constrained-relative standard deviation (c-RSD)
In order to segment the localized points in the super-resolution images into “objects” we
performed a density-based clustering algorithm (DBSCAN) (Ester et al. 1996). DBSCAN
requires two input parameters for segmentation: the minimum number of points (k) within
a search radius (epsilon). We chose a minimum number of five localizations per object as
a threshold for the segmentation (k = 5). To determine the search radius (epsilon) in an
unbiased manner, we employed the elbow method. We first calculated the 4th nearest
neighbor distances (NNDs) (k-1) between each of the localizations in the entire STORM
image. We then sorted and plotted the NNDs and determined the value corresponding to
the elbow point of this sorted distribution. The distance corresponding to the elbow point
was used as the search radius in the DBSCAN algorithm. After running the DBSCAN
algorithm on the entire STORM image, localizations were segmented into objects. In order
to classify these objects into unique classes we next extracted their features. In our
classification algorithm we considered 8 features describing each object. To determine the
most relevant features to use in the classification, we first performed a PCA analysis on
these objects to obtain the two axes corresponding to the most variation between the
localization points. The 8 features were the number of localizations per object, object area,
number of localizations in the upper-left, upper-right, lower-left, and lower-right quarters
of the object and the length corresponding to the major and minor axes of the object. To
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classify the objects based on these 8 features, we used agglomerative Hierarchical
clustering algorithm (Rokach and Maimon 2006). In Hierarchical clustering, there is no a
priori assumption on the number of classes. We found that the Hierarchical clustering
alone over-estimated the number of classes, and often objects having very similar features
were classified into distinct classes. In order to overcome this problem, we developed an
iterative Hierarchical clustering algorithm, that we named Iterative Hierarchical Clustering
(constrained-relative standard deviation (c-RSD)). We imposed a threshold on the
coefficient of variation (ratio of the standard deviation to the mean) on two of the features
(length and width of the object). First, we constructed a linkage (dendrogram tree) by
calculating the distance between each of the objects in the 8th dimensional space. After
forming the dendrogram tree, if we have N objects to classify, the closest two objects and
the remaining (N-2)-many closest objects from these two first closest objects can be
obtained. As a result, we can write a set wherein the N-many objects are sorted based on
their distances from the first two closest objects. After doing so the algorithm combines
the k-closest objects into a single class if and only if the coefficient of variation on the
major and minor axis length of the new class is still less than or equal to the imposed
threshold on the coefficient of variation (0.15). In the next step, we will perform the abovementioned algorithm iteratively on the remaining classes until the number of classes
reaches a plateau. It should be mentioned that in the second loop and so on, the
dendrogram tree is formed from the average value of the features in a class and the
restriction on the coefficient of variation is always set on the objects within a class.
As a final step we can furthermore classify the classes obtained from the Iterative
Hierarchical Clustering c-RSD into unique classes based on the visual inspection of these
classes. Any classes that visually resembled each other and that were connected in the
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dendrogram tree were furthermore combined together. Calculation of the coefficient of
variation on the major/minor axis length after this final classification step might be higher
than the 0.15 value because of the supervised step but visually they appear to belong to
the same class.
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Fig. B1: Iterative hierarchical shape classification. A. Plots showing the number of classes
identified after each iteration of the hierarchical clustering algorithm in low and high tau
aggregation cells of the Clone 4.1 maintained in Dox and expressing 4R-P301L-GFP tau.
The number of classes identified converge after about 30 iterations. B. Plots showing the
number of classes identified after each iteration of the hierarchical clustering algorithm in
GFP-nanobody, Th231 and AT8 labeled Clone 4.1 (4R-P301L-GFP tau) cells. The number
of classes identified converge after about 30 iterations. C. Examples of clusters having
<500 localizations in Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP
tau. These structures mostly represent nano-clusters with no particular shape. Scale bars
are 500nm. D. Dendrogram tree resulting from unsupervised classification showing 41
classes of tau aggregates in Clone 4.1 maintained in Dox and expressing 4R-P301L-GFP
tau and how they relate to each other. This example is derived from the analysis of Thr231,
AT8 and GFP nano stained Clone 4.1 cells. Examples of pairs of classes that were visually
similar and later manually combined into the same class are shown in red boxes. The x
axis represents the number of classes, whereas the y axis represents the z-score/height.
E. Examples of super-resolution images of pairs of classes that were visually similar and
later manually combined into the same class are shown. Shapes from Thr231 stained
Clone 4.1 cells are colored magenta, those from AT8 stained Clone 4.1 cells are colored
green and those from the GFP nanobody stained Clone 4.1 cells are colored blue. F.
Dendrogram tree after manually combining the 41 classes resulting from the unsupervised
classification into 23 classes of tau aggregates in Clone 4.1 maintained in Dox and
expressing 4R-P301L-GFP tau and how they relate to each other. This example is derived
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from the analysis of Thr231, AT8 and GFP nano stained Clone 4.1 cells. The x axis
represents the number of classes, whereas the y axis represents the z-score/height.

Fig. B2: Thr231 and AT8 antibodies specifically stain tau in Clone 4.1 but not Clone 4.0.
A. Wide-field images of GFP fluorescence in Clone 4.0 cells expressing 4R-P301L-GFP
tau after overnight Dox induction of tau expression (left panel) and fluorescence signal
from Thr231 antibody staining (Thr231, middle panel) in the same cell. Fluorescence
signal from Thr231 antibody staining in a Clone 4.1 maintained in Dox and expressing 4RP301L-GFP tau (Thr231, right panel). B. Wide-field images of GFP fluorescence in Clone
4.0 cells expressing 4R-P301L-GFP tau after overnight Dox induction of tau expression
(left panel) and fluorescence signal from AT8 antibody staining (AT8, middle panel) in the
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same cell. Fluorescence signal from AT8 antibody staining in a Clone 4.1 maintained in
Dox and expressing 4R-P301L-GFP tau (AT8, right panel).
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Fig. B3: Phosphorylation of specific tau residues is associated with a diverse range of tau
aggregates. A. Super-resolution images of tau hyperphosphorylated at residue Thr231 in
Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP tau, stained with Thr231
antibody. B. Super-resolution images of tau hyperphosphorylated at residuea
Ser202/Thr205 in Clone 4.1 cells maintained in Dox and expressing 4R-P301L-GFP tau,
stained with AT8 antibody. C. Two-color super-resolution images of Thr231 (magenta),
total tau (cyan) and overlay in Clone 4.1 cells maintained in Dox and expressing 4RP301L-GFP tau. The results of the co-localization analysis are shown in which tau colocalized with Thr231 is shown in magenta and isolated tau is shown in yellow. D. Twocolor super-resolution images of AT8 (magenta), total tau (cyan) and overlay in Clone 4.1
cells maintained in Dox and expressing 4R-P301L-GFP tau. The results of the colocalization analysis are shown in which tau co-localized with AT8 is shown in magenta
and isolated tau is shown in yellow. E. Violin plots showing the number of localizations per
segmented Voronoi object of tau that colocalizes with Thr231 or AT8 in Clone 4.1 cells
maintained in Dox and expressing 4R-P301L-GFP tau. The dashed lines indicate the
median and the dotted lines indicate the 25th and 75th percentile (Thr231: n=6 cells, n=2
experiments, AT8: n=5 cells, n=2 experiments). *, p<0.05.
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Supplementary Tables for Chapter 3

Condition

Number of clusters
(before
classification)

Number of classes
(after unsupervised
classification)

Number of
classes
(after
manually
combining
classes)

Low tau aggregation

1343

N/A

N/A

High tau aggregation

5539

N/A

N/A

Total

6882

40

22

Thr231 staining

225

N/A

N/A

AT8 staining

1913

N/A

N/A

GFP nano staining

6882

N/A

N/A

Total

9020

41

23

Table S.3.1. Number of tau aggregates and classes identified using Iterative Hierarchical
Clustering c-RSD
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Class

Number of clusters
per class

Ratio of low tau
aggregation
clusters over the
total no of low tau
aggregation
clusters in each
class

Ratio of
high tau
aggregation
clusters
over the
total no of
high tau
aggregation
clusters in
each class

1

598

0.01787044

0.10362881

2

827

0.10275503

0.12439068

3

507

0.10052122

0.06716014

4

1311

0.19136262

0.19028706

5

446

0.09828742

0.05668893

6

1066

0.2278481

0.13720888

7

276

0.04095309

0.0398989

8

595

0.10052122

0.08304748

9

281

0.03201787

0.04296804

10

337

0.0476545

0.04928687

11

67

0.00446761

0.01101282

12

302

0.02382725

0.04874526

13

97

0.00521221

0.01624842

14

10

0.0007446

0.00162484

15

76

0.00446761

0.01263766

16

30

0

0.00541614

17

28

0.0014892

0.00469399

18

3

0

0.00054161

19

18

0

0.00324968

20

1

0

0.00018054

21

5

0

0.00090269

104

22

1

0

0.00018054

Table S.3.2. Detailed quantitative description of classes from low and high tau aggregation
Clone 4.1 cells
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Class

Number of
clusters per
class

Ratio of Thr231
clusters over
the total no of
Thr231
clusters in
each class

Ratio of AT8
clusters
over the
total no of
AT8
clusters in
each class

Ratio of
GFP nano
clusters
over the
total no of
GFP nano
clusters in
each class

1

1491

0.1822222

0.1217982

0.1768381

2

635

0.0355556

0.0893884

0.0662598

3

2318

0.4266667

0.2122321

0.2638768

4

358

0.0266667

0.0627287

0.0337111

5

98

0.0088889

0.0245687

0.00712

6

1025

0.1288889

0.1003659

0.1168265

7

609

0.0622222

0.0935703

0.0604475

8

132

0.0133333

0.026137

0.0114792

9

738

0.0933333

0.0773654

0.0826795

10

592

0.0177778

0.0794564

0.0633537

11

11

0

0.0010455

0.0013078

12

110

0.0044444

0.0130685

0.0122058

13

668

0

0.0737062

0.0765766

14

44

0

0.0078411

0.0042139

15

95

0

0.0115003

0.0106074

16

12

0

0.0005227

0.0015984

17

37

0

0.0036592

0.0043592

18

11

0

0.0005227

0.0014531

19

11

0

0

0.0015984

20

18

0

0.0005227

0.0024702

21

1

0

0

0.0001453

22

5

0

0

0.0007265

106

23

1

0

0

0.0001453

Table S.3.3. Detailed quantitative description of classes from Thr231, AT8 and GFP
nanobody stained Clone 4.1 cells
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APPENDIX C.

Supplementary Materials and Methods for Chapter 4

Cell Culture
A stable human embryonic kidney-derived QBI-293 cell line (Clone 4.1) expressing full
length human tau T40 (2N4R) carrying the P301L mutation with a GFP tag, a kind gift from
the V. Lee lab at the University of Pennsylvania, was used for the majority of experiments.
Clone 4.1 was originally sorted from the parent Clone 4.0 cells to enrich for large compact
tau aggregates after exogenous tau fibril addition (J. L. Guo et al. 2016). Cells were grown
in Dulbecco’s modified Eagle’s medium supplemented with 10% tetracycline-screened
fetal bovine serum (FBS), 1% pyruvate (10mM), 1% penicillin-streptomycin and Lglutamine (20 mM), 5ug/ml blasticidin, 200ug/ml Zeozin and were maintained in a 37°C
incubator containing 5% CO2. Clone 4.1 was maintained in media containing 100ng/mL of
Doxycycline (Dox). For all imaging, cells were plated on eight-well Lab-Tek 1 coverglass
chambers (Nunc).

Cell lysate extraction and Western blotting

Cell lysate was extracted from QBI cells with Dox-regulated expression of 4R-P301L-GFP
tau (Clone 4.1 grown in Dox) by RIPA (Radioimmunoprecipitation) buffer containing
phosphatase and protease inhibitors and incubated on ice for 15 min. Lysates were then
centrifuged at maximum speed on a tabletop centrifuge for 30 min at 4 °C. Protein
concentration was determined using the Bradford assay. 2-3ug of protein per sample were
resolved in 4-12% Bis-Tris NuPAGE (polyacrylamide) gels, transferred to nitrocellulose
membranes, and blocked in Odyssey blocking buffer (Li-Cor Biosciences) before probing
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with antibodies (Table S.4.1). The blots were further incubated with IRDye labeled
secondary antibodies and scanned using ODY-2816 Imager (Li-Cor Biosciences).
GAPDH was used as a loading control. Image analysis was performed using Image Studio
Lite software (LI-COR). Fluorescent band intensity was normalized to the GAPDH loading
control.

Immunostaining

Cells were first incubated with microtubule stabilizing buffer (MTSB: 15g PIPES, 1.9g
EGTA, 1.32 MgSO4·7H2O, 5g KOH, H2O to a liter, pH=7) for 3 min and then ice cold
methanol was added in the buffer for 3 min. Following this short incubation, cells were
washed with MTSB twice. Cells were then blocked for 1hr using 4% (wt/vol) BSA in PBS.
They were then incubated with the appropriate dilution of GFP nanobody in 4% (wt/vol)
BSA in PBS. A list of antibodies/nanobodies used in this study is provided in Table S.4.1.
The nanobody we used was GFP VHH, recombinant binding protein (gt-250, Chromotek).

SMLM imaging

SMLM was acquired using an Oxford Nanoimaging system. To avoid bias, images were
randomly acquired and all acquired images were included in the analysis unless there was
substantial drift present in the images, which could not be corrected by post-processing.
The Nanoimager-S microscope had the following configuration: 405-, 488-, 561- and 640nm lasers, 498-551- and 576-620-nm band-pass filters in channel 1, and 666-705-nm
band-pass filters in channel 2, 100 x 1.4 NA oil immersion objective (Olympus), and a
Hamamatsu Flash 4 V3 sCMOS camera. Localization microscopy images were acquired
with 15 ms exposure for 50,000 frames. For multi-color SMLM, 110,000 frames with 15
109

ms exposure were acquired with sequential laser activation. The images were then
processed using the NimOS localization software (Oxford Nanoimaging).

Data analysis

Voronoi Tesselation Analysis

Localizations were exported in .csv format using the NimOS localization software and
converted to .bin files using MATLAB R2017a. The rendered SMLM images were either
cropped using the AFIB plugin in ImageJ (National Institutes of Health) or used as a whole
(Schindelin et al. 2012). Voronoi Tesselation Analysis was performed in MATLAB R2017a
similarly to (Otterstrom et al. 2019)(Levet et al. 2015)(Andronov et al. 2016). First, a
Voronoi threshold was chosen manually to define a Voronoi cluster as a collection of
Voronoi polygons with areas smaller than the given threshold. We confirmed that the
selected threshold led to proper segmentation of the super-resolution images visually. We
adjusted the threshold to achieve proper segmentation and avoid errors in cells that were
much or less dense than the majority. The x and y coordinates from the localizations were
processed by the “delaunayTriangulation” function and then the ‘Voronoidiagram” function
to generate Voronoi polygons. The Voronoi polygon areas were calculated from the
shoelace algorithm. A new molecule list assigning localizations to different channels (0-9)
according to their Voronoi area was then generated. Next, these localizations were put
into different clusters and their cluster statistics were generated and used for analysis. The
different clusters were pseudocolored based on their channel (0-9) and visualized using a
custom-written software, Insight3 (provided by B. Huang, University of California, San
Francisco, San Francisco, CA; (Huang et al. 2008).
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Principal Component Analysis

Principal Component Analysis (PCA) (F.R.S. 2010) is a data-dimensionality reduction
technique that summarizes the original data with new variables (called principal
components, or PCs), which trade a little accuracy for simplicity, and are constructed by
using a set of linear combinations of the original data variables. PCA maximizes the
explained variance of the data by finding the eigenvectors with the largest eigenvalues of
the covariance matrix. Moreover, each PC is orthogonal (i.e., uncorrelated) with any other
PC, and the first PC captures the most variance in the data, the second PC the second
most, etc. Using this approach, we were able to simplify the original data, as the later PCs
explained very little variance of the data (in most cases mainly noise), and were therefore
removed from the model. This newly constructed PCA model was used for exploration,
visualization and data analysis.
Machine Learning – Based Classification

To assess tau aggregate degradation, a supervised classification method called random
forest was used (Breiman 2001). Initially, a small subset of the data was manually
classified into four different groups (linear fibrils, branched fibrils, NFT Precursors, and
NFTs), which was used as the ground truth for the classifier. This random forest classifier
is an ensemble technique that uses a large number of so-called 'weak' classifiers (i.e.,
decision trees) that each classify the data (i.e., the shape descriptors describing the tau
aggregates) independently and then combine these results using the 'power of numbers'
principle: each tree predicts the class for each sample and the class with the most votes
is then the random forest prediction. The strength of the random forest classifier can be
explained by the fact that the large number of trees protect each other from their individual
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errors. However, the caveat here is that the different trees have to be (largely) uncorrelated
to each other, but, this can easily be obtained if each of the individual trees predict the
outcome for just a small, randomly selected, subset of variables of the training data. Once
the random forest classifier is trained, the model can be used on new data to predict the
type of tau aggregate.

Statistical Analysis

Non-parametric Mann-Whitney tests were performed using OriginPro 2017 software for
the imaging data sets in Fig. 4.1B.

Supplementary Figures for Chapter 4
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Fig. C1: Representative images of tau from +dox control and the 1-10 days off dox experiments. A.
Super-resolution images of tau in Clone 4.1 cells maintained in dox media, stained with a GFP
nanobody conjugated to AlexaFluor 647. B-G. Super-resolution images of tau in Clone 4.1 cells
where dox has been removed for 1 day (B), 2 days (C), 3 days (D), 4 days (E), 5 days (F), 10 days
(G).

Fig. C2: PCA reveals similarities in tau aggregate structures from +dox control, Day 1 and Day 2
off dox. A. PCA plot for tau aggregates from cells from +dox control (red), Day 1 (green), Day 2
(blue). B. PCA plot of all the linear fibrils from cells from +dox control (red), Day 1 (green), Day 2
(blue). C. PCA plot of all the branched fibrils from cells from +dox control (red), Day 1 (green), Day
2 (blue). D. PCA plot of all the NFT Precursors from cells from +dox control (red), Day 1 (green),
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Day 2 (blue). E. PCA plot of all the NFTs from cells from +dox control (red), Day 1 (green), Day 2
(blue). F. PCA plot of the linear fibrils (red), branched fibrils (green), NFT Precursors (blue) NFTs
(cyan) from cells from +dox control, Day 1 and Day 2 off dox.

Fig. C3: PCA reveals differences in tau aggregate structures from different days off dox. PCA plot
for tau aggregates from cells from +dox control (grey), Day 1 (grey), Day 2 (grey), Day 3 (magenta),
Day 4 (green), Day 5 (red) and Day 10 off dox (blue).
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Fig. C4: Treatment with CQ leads to autophagy inhibition. A. Western Blot showing tau, GAPDH
(loading control) and LC3-I and II from lysates of Clone 4.1 cells cultured in the presence of Dox
(+dox), or the absence of Dox for 1 day in culture (-dox) or the absence of Dox for 1 day in culture
and in the presence of 30 μM CQ (-dox CQ). B. Western Blot showing tau, GAPDH (loading control)
and LC3-I and II from lysates of Clone 4.1 cells cultured in the presence of Dox (+dox), or the
absence of Dox for 2 days in culture (-dox) or the absence of Dox for 2 days in culture and in the
presence of 30 μM CQ (-dox CQ). Clone 4.0 cells transfected with an LC3-plasmid (GFP-RFP) that
have been in media without dox for two days (C) or two days in addition to being treated with 30
μM CQ (D). Scale bar of inset is 5 μm.
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Fig. C5: Treatment with epo leads to proteasome inhibition. A. Western Blot showing tau, Ub
(green), Tau, and GAPDH (loading control from lysates of Clone 4.1 cells cultured in the presence
of Dox (+dox), or the absence of Dox for 1 day in culture (-dox) or the absence of Dox for 1 day in
culture and in the presence of 20 nM CQ (-dox epo). B. Quantification of signal from two Western
blot replicates in A. Error bars indicate standard deviation (SD).

Fig. C6: PCA reveals differences in tau aggregate structures from CQ treatment versus epo
treatment. A, B. 2-D and 3-D PCA plot of tau aggregates from cells from Day 1(red), Day 1 CQ
(blue), Day 1 epo (green).
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Antibody

Host species

Catalog number

Vendor

α-tubulin

Rabbit

ab18251

Abcam

Ubiquitin

Rabbit

E4I2J

Cell Signaling
Technology

LC3

Rabbit

ab48394

Abcam

GFP Binding
Protein

Alpaca

gt-250

ChromoTek

Tau-5

Mouse

AHB0042

ThermoFisher
Scientific

GAPDH

Mouse

A01622-40

GenScript

Table S.4.1. Antibodies used in this study
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